

Edoardo Savarino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3921776/publications.pdf>

Version: 2024-02-01

657
papers

20,951
citations

15504

65
h-index

16183

124
g-index

667
all docs

667
docs citations

667
times ranked

10985
citing authors

#	ARTICLE	IF	CITATIONS
1	The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterology and Motility, 2015, 27, 160-174.	3.0	1,628
2	Modern diagnosis of GERD: the Lyon Consensus. Gut, 2018, 67, 1351-1362.	12.1	991
3	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis, 2020, 14, 4-22.	1.3	741
4	A Comparison of Five Maintenance Therapies for Reflux Esophagitis. New England Journal of Medicine, 1995, 333, 1106-1110.	27.0	542
5	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. Journal of Crohn's and Colitis, 2020, 14, 155-168.	1.3	478
6	Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0. Neurogastroenterology and Motility, 2021, 33, e14058.	3.0	468
7	Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 908-917.	8.1	359
8	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis, 2022, 16, 2-17.	1.3	288
9	Ambulatory reflux monitoring for diagnosis of gastroesophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterology and Motility, 2017, 29, 1-15.	3.0	275
10	Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 359-370.	8.1	256
11	Gastroesophageal Reflux and Pulmonary Fibrosis in Scleroderma. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 408-413.	5.6	251
12	The Role of Nonacid Reflux in NERD: Lessons Learned From Impedance-pH Monitoring in 150 Patients off Therapy. American Journal of Gastroenterology, 2008, 103, 2685-2693.	0.4	224
13	Analyses of the Post-reflux Swallow-induced Peristaltic Wave Index and Nocturnal Baseline Impedance Parameters Increase the Diagnostic Yield of Impedance-pH Monitoring of Patients With Reflux Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 40-46.	4.4	222
14	The 2018 ISDE achalasia guidelines. Ecological Management and Restoration, 2018, 31, .	0.4	221
15	Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. Journal of Allergy and Clinical Immunology, 2018, 141, 1365-1372.	2.9	208
16	Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut, 2009, 58, 1185-1191.	12.1	206
17	Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. European Respiratory Journal, 2013, 42, 1322-1331.	6.7	194
18	EAES recommendations for the management of gastroesophageal reflux disease. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1753-1773.	2.4	194

#	ARTICLE	IF	CITATIONS
19	Reassessment of the Diagnostic Value of Histology in Patients with GERD, Using Multiple Biopsy Sites and an Appropriate Control Group. American Journal of Gastroenterology, 2005, 100, 2299-2306.	0.4	192
20	Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance-pH Off Therapy. American Journal of Gastroenterology, 2010, 105, 1053-1061.	0.4	190
21	Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial. American Journal of Gastroenterology, 2013, 108, 1731-1742.	0.4	187
22	Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. Neurogastroenterology and Motility, 2014, 26, 546-555.	3.0	185
23	NERD: an umbrella term including heterogeneous subpopulations. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 371-380.	17.8	184
24	The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. European Journal of Internal Medicine, 2017, 37, 19-24.	2.2	184
25	Small Intestinal Bacterial Overgrowth in Rosacea: Clinical Effectiveness of Its Eradication. Clinical Gastroenterology and Hepatology, 2008, 6, 759-764.	4.4	177
26	Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 476-486.	3.7	172
27	Classification of esophageal motor findings in gastroesophageal reflux disease: Conclusions from an international consensus group. Neurogastroenterology and Motility, 2017, 29, e13104.	3.0	158
28	Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. Journal of Gastroenterology, 2013, 48, 473-482.	5.1	157
29	Advances in the physiological assessment and diagnosis of GERD. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 665-676.	17.8	157
30	Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacological Research, 2009, 59, 135-153.	7.1	156
31	The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 542-547.	0.9	140
32	Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Digestive and Liver Disease, 2006, 38, 226-232.	0.9	139
33	Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointestinal Endoscopy, 1996, 44, 700-705.	1.0	135
34	Long-Term Safety of In Utero Exposure to Anti-TNF α Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. American Journal of Gastroenterology, 2018, 113, 396-403.	0.4	134
35	How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?. World Journal of Gastroenterology, 2012, 18, 4363.	3.3	132
36	High-resolution Impedance Manometry after Sleeve Gastrectomy: Increased Intra-gastric Pressure and Reflux are Frequent Events. Obesity Surgery, 2016, 26, 2449-2456.	2.1	124

#	ARTICLE	IF	CITATIONS
37	Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1082-1088.e1.	4.4	121
38	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 179-189.	1.3	120
39	Effects of omega-loop bypass on esophagogastric junction function. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 62-69.	1.2	117
40	Small Intestinal Bacterial Overgrowth in Patients Suffering From Scleroderma: Clinical Effectiveness of Its Eradication. <i>American Journal of Gastroenterology</i> , 2008, 103, 1257-1262.	0.4	114
41	Proton pump inhibitors: use and misuse in the clinical setting. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1123-1134.	3.1	112
42	Postreflux swallowâ€induced peristaltic wave index and nocturnal baseline impedance can link <sc>PPI</sc>â€responsive heartburn to reflux better than acid exposure time. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13116.	3.0	107
43	The added diagnostic value of postreflux swallowâ€induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with onâ€therapy impedanceâ€pH monitoring. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12947.	3.0	107
44	Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 638-648.	8.1	105
45	Therapeutic potential of curcumin in digestive diseases. <i>World Journal of Gastroenterology</i> , 2013, 19, 9256.	3.3	103
46	Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. <i>Journal of Gastroenterology</i> , 2012, 47, 159-168.	5.1	102
47	Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. <i>Nutrition</i> , 2006, 22, 334-342.	2.4	96
48	Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. <i>Journal of Gastroenterology</i> , 2017, 52, 444-451.	5.1	96
49	OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. <i>American Journal of Gastroenterology</i> , 2018, 113, 1621-1628.	0.4	96
50	Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naïve patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. <i>Lancet, The</i> , 2022, 399, 2200-2211.	13.7	94
51	Esophagogastric junction morphology is associated with a positive impedanceâ€<sc>pH</sc> monitoring in patients with <sc>GERD</sc>. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1175-1182.	3.0	91
52	Gastrointestinal motility disorder assessment in systemic sclerosis. <i>Rheumatology</i> , 2013, 52, 1095-1100.	1.9	87
53	Esophagogastric junction contractility for clinical assessment in patients with <sc>GERD</sc>: a real added value?. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1423-1431.	3.0	85
54	Use of the Functional Lumen Imaging Probe in Clinical Esophagology. <i>American Journal of Gastroenterology</i> , 2020, 115, 1786-1796.	0.4	84

#	ARTICLE	IF	CITATIONS
55	Practice guidelines on the use of esophageal manometry â€“ A GISMA-SIGE-AIGO medical position statement. Digestive and Liver Disease, 2016, 48, 1124-1135.	0.9	82
56	A 10-day levofloxacin-based therapy in patients with resistant infection: A controlled trial. Clinical Gastroenterology and Hepatology, 2004, 2, 997-1002.	4.4	80
57	How to select patients for antireflux surgery? The ICARUS guidelines (international consensus) Tj ETQq1 1 0.784314 rgBT /Overlock 1	12.1	80
58	Validation of criteria for the definition of transient lower esophageal sphincter relaxations using highâ€‘resolution manometry. Neurogastroenterology and Motility, 2017, 29, e12920.	3.0	78
59	Ineffective esophageal motility: Concepts, future directions, and conclusions from the Stanford 2018 symposium. Neurogastroenterology and Motility, 2019, 31, e13584.	3.0	76
60	Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux. Digestive and Liver Disease, 2004, 36, 565-569.	0.9	75
61	Endoscopic management of gastrointestinal motility disorders â€“ part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2020, 52, 498-515.	1.8	75
62	An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pHâ€‘metry. Alimentary Pharmacology and Therapeutics, 2005, 21, 29-34.	3.7	74
63	Proton pump inhibitor responders who are not confirmed as <scp>GERD</scp> patients with impedance and pH monitoring: who are they?. Neurogastroenterology and Motility, 2014, 26, 28-35.	3.0	73
64	Characteristics of gastro-esophageal reflux episodes in Barrettâ€™s esophagus, erosive esophagitis and healthy volunteers. Neurogastroenterology and Motility, 2010, 22, 1061-e280.	3.0	72
65	Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Alimentary Pharmacology and Therapeutics, 2020, 52, 798-807.	3.7	72
66	Endoscopic tissue sampling â€“ Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2021, 53, 1174-1188.	1.8	71
67	Optimal treatment of laryngopharyngeal reflux disease. Therapeutic Advances in Chronic Disease, 2013, 4, 287-301.	2.5	70
68	Endoscopic management of gastrointestinal motility disorders â€“ part 2: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2020, 52, 600-614.	1.8	70
69	Esophageal motility abnormalities in gastroesophageal reflux disease. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2014, 5, 86.	1.1	68
70	Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Annals of Gastroenterology, 2018, 31, 639-648.	0.6	68
71	Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterology and Motility, 2020, 32, e13914.	3.0	68
72	ESNM/ANMS consensus paper: Diagnosis and management of refractory gastroâ€™esophageal reflux disease. Neurogastroenterology and Motility, 2021, 33, e14075.	3.0	68

#	ARTICLE	IF	CITATIONS
73	Are proton pump inhibitors really so dangerous?. Digestive and Liver Disease, 2016, 48, 851-859.	0.9	66
74	Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives. Digestive Diseases and Sciences, 2017, 62, 1881-1889.	2.3	66
75	Mean Nocturnal Baseline Impedance Correlates With Symptom Outcome When Acid Exposure Time Is Inconclusive on Esophageal Reflux Monitoring. Clinical Gastroenterology and Hepatology, 2020, 18, 589-595.	4.4	66
76	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology, 2020, 158, 515-526.e10.	1.3	65
77	Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough. Alimentary Pharmacology and Therapeutics, 2014, 40, 966-973.	3.7	63
78	Vigor of peristalsis during multiple rapid swallows is inversely correlated with acid exposure time in patients with NERD. Neurogastroenterology and Motility, 2016, 28, 243-250.	3.0	63
79	Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Alimentary Pharmacology and Therapeutics, 2010, 32, 1000-1006.	3.7	62
80	Achalasia With Dense Eosinophilic Infiltrate Responds to Steroid Therapy. Clinical Gastroenterology and Hepatology, 2011, 9, 1104-1106.	4.4	62
81	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. United European Gastroenterology Journal, 2021, 9, 307-331.	3.8	62
82	Management Strategy for Patients With Gastroesophageal Reflux Disease: A Comparison Between Empirical Treatment With Esomeprazole and Endoscopy-Oriented Treatment. American Journal of Gastroenterology, 2008, 103, 267-275.	0.4	60
83	Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn. American Journal of Gastroenterology, 2018, 113, 670-676.	0.4	60
84	COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine. Digestive and Liver Disease, 2020, 52, 1071-1075.	0.9	60
85	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European Gastroenterology Journal, 2021, 9, 287-306.	3.8	60
86	Positive Glucose Breath Testing is More Prevalent in Patients With IBS-like Symptoms Compared With Controls of Similar Age and Gender Distribution. Journal of Clinical Gastroenterology, 2009, 43, 962-966.	2.2	59
87	Alginate controls heartburn in patients with erosive and nonerosive reflux disease. World Journal of Gastroenterology, 2012, 18, 4371.	3.3	59
88	Gastrointestinal involvement in systemic sclerosis. Presse Medicale, 2014, 43, e279-e291.	1.9	59
89	Excellent agreement between genetic and hydrogen breath tests for lactase deficiency and the role of extended symptom assessment. British Journal of Nutrition, 2010, 104, 900-907.	2.3	55
90	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. American Journal of Gastroenterology, 2016, 111, 1711-1717.	0.4	55

#	ARTICLE	IF	CITATIONS
91	High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in vivo evaluation. United European Gastroenterology Journal, 2018, 6, 981-989.	3.8	55
92	Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101521.	1.5	55
93	Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: A national survey. Digestive and Liver Disease, 2020, 52, 808-815.	0.9	54
94	Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy. Alimentary Pharmacology and Therapeutics, 2009, 30, 508-515.	3.7	53
95	Overweight is a risk factor for both erosive and non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 940-945.	0.9	52
96	Helicobacter Pylori Infection Does Not Protect Against Eosinophilic Esophagitis: Results From a Large Multicenter Case-Control Study. American Journal of Gastroenterology, 2018, 113, 972-979.	0.4	52
97	Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice. Clinical Gastroenterology and Hepatology, 2020, 18, 2903-2911.e4.	4.4	51
98	Functional Heartburn and Non-Erosive Reflux Disease. Digestive Diseases, 2007, 25, 172-174.	1.9	49
99	The natural history of gastro-esophageal reflux disease: a comprehensive review. Ecological Management and Restoration, 2016, 30, 1-9.	0.4	49
100	Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. Ecological Management and Restoration, 2016, 29, 197-204.	0.4	49
101	Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. Gut, 2021, 70, 1441-1449.	12.1	49
102	Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study. BMJ Open Gastroenterology, 2021, 8, e000578.	2.7	49
103	Ultrasound-guided core-needle biopsy of extra-ocular orbital lesions. European Radiology, 2013, 23, 1919-1924.	4.5	46
104	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Gastroenterology, 2021, 161, 1865-1877.	1.3	46
105	The appropriate use of proton-pump inhibitors. Minerva Medica, 2018, 109, 386-399.	0.9	46
106	Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World Journal of Gastroenterology, 2013, 19, 5787.	3.3	46
107	Inter-reviewer Variability in Interpretation of pH-Impedance Studies: The Wingate Consensus. Clinical Gastroenterology and Hepatology, 2021, 19, 1976-1978.e1.	4.4	45
108	Influence of Diet on the Course of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2017, 62, 2087-2094.	2.3	44

#	ARTICLE	IF	CITATIONS
109	Optimal number of multiple rapid swallows needed during high-resolution esophageal manometry for accurate prediction of contraction reserve. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13253.	3.0	44
110	Eosinophilic esophagitis: Update in diagnosis and management. Position paper by the Italian Society of Gastroenterology and Gastrointestinal Endoscopy (SIGE). <i>Digestive and Liver Disease</i> , 2017, 49, 254-260.	0.9	43
111	Vonoprazan fumarate for the management of acid-related diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1145-1152.	1.8	43
112	Indications and interpretation of esophageal function testing. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 239-253.	3.8	43
113	Microscopic esophagitis in gastro-esophageal reflux disease: individual lesions, biopsy sampling, and clinical correlations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 31-39.	2.8	42
114	A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. <i>Nutrition</i> , 2019, 67-68, 110542.	2.4	42
115	<p>Idiopathic pulmonary fibrosis and GERD: links and risks</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1081-1093.	2.0	42
116	Role of Reflux in the Pathogenesis of Eosinophilic Esophagitis: Comprehensive Appraisal With Off- and On PPI Impedance-pH Monitoring. <i>American Journal of Gastroenterology</i> , 2019, 114, 1606-1613.	0.4	42
117	Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors “ A cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 507.	3.3	42
118	Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastroesophageal reflux disease according to Lyon Consensus. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 412-418.	3.7	42
119	Characteristics of the Esophageal Low-Pressure Zone in Healthy Volunteers and Patients With Esophageal Symptoms: Assessment by High-Resolution Manometry. <i>American Journal of Gastroenterology</i> , 2008, 103, 2544-2549.	0.4	41
120	Evidence of Prolonged Orocecal Transit Time and Small Intestinal Bacterial Overgrowth in Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2119-2124.	3.6	40
121	Management of Osteoarthritis: Expert Opinion on NSAIDs. <i>Pain and Therapy</i> , 2021, 10, 783-808.	3.2	40
122	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	2.9	40
123	Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482098086.	3.2	40
124	Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. <i>United European Gastroenterology Journal</i> , 2022, 10, 556-584.	3.8	40
125	A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1333-1343.	1.8	39
126	The “three-in-one” formulation of bismuth quadruple therapy for <i>Helicobacter pylori</i> eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. <i>Helicobacter</i> , 2018, 23, e12502.	3.5	39

#	ARTICLE	IF	CITATIONS
127	Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1579-1587.	1.9	39
128	Autoimmune gastritis: long-term natural history in naïve <i>Helicobacter pylori</i> -negative patients. <i>Gut</i> , 2023, 72, 30-38.	12.1	39
129	Variability in individual response to various doses of omeprazole. <i>Digestive Diseases and Sciences</i> , 1994, 39, 161-168.	2.3	38
130	Ultrasound-guided procedures around the wrist and hand: How to do. <i>European Journal of Radiology</i> , 2014, 83, 1231-1238.	2.6	38
131	The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a <scp>GERD</scp>-related phenomenon. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 522-530.	3.7	38
132	Superior Mesenteric Artery Syndrome: a Prospective Study in a Single Institution. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 997-1005.	1.7	38
133	Normal values of esophageal motility after antireflux surgery; a study using high-resolution manometry. <i>Neurogastroenterology and Motility</i> , 2015, 27, 929-935.	3.0	37
134	Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-10.	1.5	37
135	Esophageal High-Resolution Manometry Can Unravel the Mechanisms by Which Different Bariatric Techniques Produce Different Reflux Exposures. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1-7.	1.7	37
136	Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 525.	8.1	37
137	Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 335-339.	1.3	37
138	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1081-1086.	1.5	36
139	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.9	36
140	Achalasia. <i>Nature Reviews Disease Primers</i> , 2022, 8, 28.	30.5	36
141	Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia. <i>World Journal of Gastroenterology</i> , 2013, 19, 2668.	3.3	35
142	Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2016, , CD009034.	2.8	35
143	Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence. <i>Cancers</i> , 2021, 13, 3162.	3.7	35
144	Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1554-1563.	4.4	34

#	ARTICLE	IF	CITATIONS
145	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 362-371.	0.4	34
146	Refractory Gastroesophageal Reflux Disease: A Management Update. <i>Frontiers in Medicine</i> , 2021, 8, 765061.	2.6	34
147	Microscopic esophagitis and Barrett's esophagus: The histology report. <i>Digestive and Liver Disease</i> , 2011, 43, S319-S330.	0.9	33
148	In-vivo Axial-strain Sonoelastography Helps Distinguish Acutely-inflamed from Fibrotic Terminal Ileum Strictures in Patients with Crohn's Disease: Preliminary Results. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 855-863.	1.5	32
149	Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1074-1081.	3.7	32
150	Fragmented and failed swallows on esophageal high-resolution manometry associate with abnormal reflux burden better than weak swallows. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13736.	3.0	32
151	Application of Lyon Consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters. <i>Gut</i> , 2022, 71, 1062-1067.	12.1	32
152	A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux Symptoms. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1904-1909.	2.3	31
153	Updates in the field of non-esophageal gastroesophageal reflux disorder. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 827-838.	3.0	31
154	Combined multichannel intraluminal impedance and manometry testing. <i>Digestive and Liver Disease</i> , 2008, 40, 167-173.	0.9	30
155	The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1361-1369.	3.3	30
156	Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) â€” Study section â€œDigestive Diseases in Primary Careâ€”. <i>Digestive and Liver Disease</i> , 2018, 50, 894-902.	0.9	30
157	Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. <i>Digestive and Liver Disease</i> , 2021, 53, 1479-1485.	0.9	30
158	Gastritis: The clinico-pathological spectrum. <i>Digestive and Liver Disease</i> , 2021, 53, 1237-1246.	0.9	30
159	Epidemiology and natural history of gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , 2017, 63, 175-183.	0.5	30
160	Endoscopic tissue sampling â€” Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. <i>Endoscopy</i> , 2021, 53, 1261-1273.	1.8	30
161	Lactulose Breath Test to Assess Oro-cecal Transit Delay and Estimate Esophageal Dysmotility in Scleroderma Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 522-529.	3.4	29
162	A Comparison Between Lactose Breath Test and Quick Test on Duodenal Biopsies for Diagnosing Lactase Deficiency in Patients With Self-reported Lactose Intolerance. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 148-152.	2.2	29

#	ARTICLE	IF	CITATIONS
163	Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 762-773.	3.7	29
164	Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. <i>Annals of Gastroenterology</i> , 2017, 31, 1-7.	0.6	28
165	Quantification of visceral adipose tissue by computed tomography and magnetic resonance imaging: reproducibility and accuracy. <i>Radiologia Brasileira</i> , 2019, 52, 1-6.	0.7	28
166	Diagnostic delay and misdiagnosis in eosinophilic oesophagitis. <i>Digestive and Liver Disease</i> , 2021, 53, 1632-1639.	0.9	28
167	Jackhammer esophagus with and without esophagogastric junction outflow obstruction demonstrates altered neural control resembling type 3 achalasia. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13678.	3.0	27
168	Provocative testing in patients with jackhammer esophagus: evidence for altered neural control. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G397-G403.	3.4	27
169	Correlation between reflux burden, peristaltic function, and mucosal integrity in GERD patients. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13752.	3.0	27
170	A SICE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. <i>Digestive and Liver Disease</i> , 2020, 52, 966-980.	0.9	27
171	Value of pH Impedance Monitoring While on Twice-Daily Proton Pump Inhibitor Therapy to Identify Need for Escalation of Reflux Management. <i>Gastroenterology</i> , 2021, 161, 1412-1422.	1.3	27
172	Systematic review with meta-analysis: artificial intelligence in the diagnosis of oesophageal diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 528-540.	3.7	27
173	Drugs for improving esophageal mucosa defense: where are we now and where are we going?. <i>Annals of Gastroenterology</i> , 2017, 30, 585-591.	0.6	26
174	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 480-489.	1.3	26
175	The Lyon Consensus: Does It Differ From the Previous Ones?. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 311-321.	2.4	26
176	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1184-1196.	1.3	26
177	Esophageal testing: What we have so far. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2016, 7, 72.	1.0	26
178	A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach. <i>Gut Microbes</i> , 2022, 14, 2028366.	9.8	26
179	Comparison of the Effects of Placebo, Ranitidine, Famotidine and Nizatidine on Intragastric Acidity by Means of Continuous pH Recording. <i>Digestion</i> , 1989, 42, 1-6.	2.3	25
180	Eosinophilic oesophagitis: From physiopathology to treatment. <i>Digestive and Liver Disease</i> , 2013, 45, 871-878.	0.9	25

#	ARTICLE	IF	CITATIONS
181	Between GERD and NERD: the relevance of weakly acidic reflux. <i>Annals of the New York Academy of Sciences</i> , 2016, 1380, 218-229.	3.8	25
182	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the LÃ©mann Index. <i>Digestive and Liver Disease</i> , 2017, 49, 175-180.	0.9	25
183	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IBD study. <i>Digestive and Liver Disease</i> , 2019, 51, 972-977.	0.9	25
184	Latest insights into the hot question of proton pump inhibitor safety – a narrative review. <i>Digestive and Liver Disease</i> , 2020, 52, 842-852.	0.9	25
185	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <scp>IG-IBD LIVE</scp> study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109.	3.7	25
186	The impact of bariatric surgery on esophageal function. <i>Annals of the New York Academy of Sciences</i> , 2016, 1381, 98-103.	3.8	24
187	A safety review of proton pump inhibitors to treat acid-related digestive diseases. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 785-794.	2.4	24
188	Artificial intelligence automates and augments baseline impedance measurements from pH-impedance studies in gastroesophageal reflux disease. <i>Journal of Gastroenterology</i> , 2021, 56, 34-41.	5.1	24
189	Hypercontractile Esophagus From Pathophysiology to Management: Proceedings of the Pisa Symposium. <i>American Journal of Gastroenterology</i> , 2021, 116, 263-273.	0.4	24
190	Applying Lyon Consensus criteria in the work-up of patients with proton pump inhibitory-refractory heartburn. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1423-1430.	3.7	24
191	Management of <i>Helicobacter pylori</i> infection: Guidelines of the Italian Society of Gastroenterology (SIGE) and the Italian Society of Digestive Endoscopy (SIED). <i>Digestive and Liver Disease</i> , 2022, 54, 1153-1161.	0.9	24
192	Adalimumab for the prevention of recurrence after surgery for Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 863-864.	1.6	23
193	Glucose transporter expression in the human colon. <i>World Journal of Gastroenterology</i> , 2018, 24, 775-793.	3.3	23
194	Risk of COVID-19 in celiac disease patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102639.	5.8	23
195	High-Resolution Manometry Thresholds and Motor Patterns Among Asymptomatic Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e398-e406.	4.4	23
196	Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13919.	3.0	23
197	Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-1 prospective trials in 81 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 629-636.	3.7	23
198	Post-reflux swallow-induced peristaltic wave (PSPW): physiology, triggering factors and role in reflux clearance in healthy subjects. <i>Journal of Gastroenterology</i> , 2020, 55, 1109-1118.	5.1	23

#	ARTICLE	IF	CITATIONS
199	Effectiveness and Safety of Pylera® in Patients Infected by <i>Helicobacter Pylori</i> : A Multicenter, Retrospective, Real Life Study. <i>Digestive Diseases</i> , 2018, 36, 264-268.	1.9	22
200	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 452-456.	0.9	22
201	The natural history of achalasia: Evidence of a continuum – The evolutive pattern theory. <i>Digestive and Liver Disease</i> , 2018, 50, 342-347.	0.9	22
202	Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e923-e944.	4.4	22
203	Artificial Intelligence in the Diagnosis of Upper Gastrointestinal Diseases. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 23-35.	2.2	22
204	Improvement in Esophageal Motor Abnormalities in Systemic Sclerosis Patients Treated with Cyclosporine: Comment on the Article by Clements et al. <i>Arthritis and Rheumatism</i> , 1994, 37, 301-302.	6.7	21
205	Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. <i>Journal of Hepatology</i> , 1996, 25, 152-157.	3.7	21
206	Optimizing Symptom Relief and Preventing Complications in Adults with Gastro-Oesophageal Reflux Disease. <i>Digestion</i> , 2004, 69, 9-16.	2.3	21
207	Prevention of postoperative recurrence of Crohn's disease by Adalimumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 24, 1.	1.6	21
208	Dysmotility and reflux disease. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2013, 21, 1.	1.8	21
209	Esophagogastric junction morphology assessment by high resolution manometry in obese patients candidate to bariatric surgery. <i>International Journal of Surgery</i> , 2016, 28, S109-S113.	2.7	21
210	Psoriasis and small intestine bacterial overgrowth. <i>International Journal of Dermatology</i> , 2018, 57, 112-113.	1.0	21
211	Bowel Sonoelastography in Patients with Crohn's Disease: A Systematic Review. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 297-302.	1.5	21
212	Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 756-763.	1.9	21
213	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Review of Clinical Pharmacology, 2020, 13, 437-449.	3.1	21
214	Elimination of Dietary Triggers Is Successful in Treating Symptoms of Gastroesophageal Reflux Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1565-1571.	2.3	21
215	Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Design, Development and Therapy, 2021, Volume 15, 1609-1621.	4.3	21
216	Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. <i>Scientific Reports</i> , 2021, 11, 10368.	3.3	21

#	ARTICLE	IF	CITATIONS
217	Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. <i>Nutrients</i> , 2021, 13, 1630.	4.1	21
218	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14238.	3.0	21
219	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 451-456.	0.9	21
220	The Impact of Heller Myotomy on Integrated Relaxation Pressure in Esophageal Achalasia. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 125-131.	1.7	20
221	Eosinophilic esophagitis: latest insights from diagnosis to therapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 84-93.	3.8	20
222	Esophageal mucosal innervation in functional heartburn: Closer to healthy asymptomatic subjects than to non-erosive reflux disease patients. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13667.	3.0	20
223	Esophageal pH increments associated with post-reflux swallow-induced peristaltic waves show the occurrence and relevance of esophago-salivary reflex in clinical setting. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14085.	3.0	20
224	Systematic Review: esophageal motility patterns in patients with eosinophilic esophagitis. <i>Digestive and Liver Disease</i> , 2022, 54, 1143-1152.	0.9	20
225	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3134.	2.4	19
226	High-resolution Manometry Determinants of Refractoriness of Reflux Symptoms to Proton Pump Inhibitor Therapy. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 447-454.	2.4	19
227	Chicago Classification Update (v4.0): Technical review on diagnostic criteria for hypercontractile esophagus. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14115.	3.0	19
228	Prevention Strategies for Esophageal Cancer—An Expert Review. <i>Cancers</i> , 2021, 13, 2183.	3.7	19
229	Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry. <i>United European Gastroenterology Journal</i> , 2022, 10, 507-517.	3.8	19
230	Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. <i>Digestive Diseases and Sciences</i> , 1998, 43, 459-463.	2.3	18
231	Barrett's esophagus in 2016: From pathophysiology to treatment. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 190.	1.1	18
232	Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease?. <i>Digestive and Liver Disease</i> , 2017, 49, 728-730.	0.9	18
233	Medical and gastroenterological education during the COVID-19 outbreak. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 447-449.	17.8	18
234	Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2741-2752.e6.	4.4	18

#	ARTICLE	IF	CITATIONS
235	Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 278-295.	3.8	17
236	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. <i>Digestive and Liver Disease</i> , 2014, 46, 1043-1046.	0.9	17
237	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1333-1341.	3.3	17
238	Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	1.5	17
239	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e89-e101.	4.4	17
240	Increased visceral sensitivity, elevated anxiety, and depression levels in patients with functional esophageal disorders and non-erosive reflux disease. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14177.	3.0	17
241	Can <i>Helicobacter pylori</i> Eradication Regimens be Shortened in Clinical Practice? An Open-label, Randomized, Pilot Study of 4 and 7-day Triple Therapy With Rabeprazole, High-dose Levofloxacin, and Tinidazole. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 515-520.	2.2	16
242	Ultrasound-guided percutaneous injection of triamcinolone acetonide for treating capsular contracture in patients with augmented and reconstructed breast. <i>European Radiology</i> , 2011, 21, 575-581.	4.5	16
243	Radiofrequency Catheter Ablation for Atrial Fibrillation Elicited "Jackhammer Esophagus": A New Complication Due to Vagal Nerve Stimulation?. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 612-615.	2.4	16
244	Quality of life after laparoscopic sigmoid resection for uncomplicated diverticular disease. <i>International Journal of Colorectal Disease</i> , 2018, 33, 513-523.	2.2	16
245	Quality-of-Life Evaluation in Coeliac Patients on a Gluten-Free Diet. <i>Nutrients</i> , 2020, 12, 2981.	4.1	16
246	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235.	3.8	16
247	Esophageal reflux hypersensitivity: Non-GERD or still GERD?. <i>Digestive and Liver Disease</i> , 2020, 52, 1413-1420.	0.9	16
248	Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak. <i>Journal of Clinical Medicine</i> , 2020, 9, 2011.	2.4	16
249	Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199990.	3.2	16
250	Noninfectious interstitial lung disease during infliximab therapy: Case report and literature review. <i>World Journal of Gastroenterology</i> , 2013, 19, 5377.	3.3	16
251	Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogastric junction outflow obstruction. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 606-613.	3.7	16
252	Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure. <i>Ecological Management and Restoration</i> , 2016, 29, 3-9.	0.4	15

#	ARTICLE	IF	CITATIONS
253	Curriculum for neurogastroenterology and motility training: A report from the joint ANMS-ESNM task force. Neurogastroenterology and Motility, 2018, 30, e13341.	3.0	15
254	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic. Neurogastroenterology and Motility, 2020, 32, e13930.	3.0	15
255	Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak. Digestive and Liver Disease, 2020, 52, 604-605.	0.9	15
256	European Society for Neurogastroenterology and Motility (ESNM) recommendations for the use of high-resolution manometry of the esophagus. Neurogastroenterology and Motility, 2021, 33, e14043.	3.0	15
257	Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action. Alimentary Pharmacology and Therapeutics, 2021, 53, 1183-1189.	3.7	15
258	Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study. Journal of Medical Internet Research, 2020, 22, e19574.	4.3	15
259	The Risk of Malignancies in Celiac Disease—A Literature Review. Cancers, 2021, 13, 5288.	3.7	15
260	The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease. European Journal of Gastroenterology and Hepatology, 2009, 21, 394-408.	1.6	14
261	Ultrasound Assessment of the Rotator Cuff Cable: Comparison Between Young and Elderly Asymptomatic Volunteers and Interobserver Reproducibility. Ultrasound in Medicine and Biology, 2012, 38, 35-41.	1.5	14
262	Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> in Crohn's disease: pharmacological and clinical implications. Expert Opinion on Biological Therapy, 2019, 19, 79-88.	3.1	14
263	Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. Clinical and Translational Gastroenterology, 2020, 11, e00177.	2.5	14
264	Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. Clinical and Experimental Gastroenterology, 2020, Volume 13, 99-104.	2.3	14
265	Postreflux swallow-induced peristaltic wave index from pH-impedance monitoring associates with esophageal body motility and esophageal acid burden. Neurogastroenterology and Motility, 2021, 33, e13973.	3.0	14
266	The Role of Wireless Capsule Endoscopy (WCE) in the Detection of Occult Primary Neuroendocrine Tumors. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 151-156.	0.9	14
267	Measurement of oro-caecal transit time by magnetic resonance imaging. European Radiology, 2015, 25, 1579-1587.	4.5	13
268	Elaprazole for the treatment of gastro-esophageal reflux. Expert Opinion on Pharmacotherapy, 2016, 17, 2107-2113.	1.8	13
269	Effects of laparoscopic myotomy on the esophageal motility pattern of esophageal achalasia as measured by high-resolution manometry. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 3510-3518.	2.4	13
270	Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093653.	3.2	13

#	ARTICLE	IF	CITATIONS
271	Inflammatory Bowel Disease and Sleep Disturbance: As Usual, Quality Matters. Digestive Diseases and Sciences, 2021, 66, 3-4.	2.3	13
272	EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210742.	3.2	13
273	PPI-based triple therapy in the eradication of H. pylori infection. Gastroenterology, 1999, 117, 746-747.	1.3	12
274	Barrett's esophagus: proton pump inhibitors and chemoprevention II. Annals of the New York Academy of Sciences, 2011, 1232, 114-139.	3.8	12
275	Functional testing: pharyngeal pH monitoring and high-resolution manometry. Annals of the New York Academy of Sciences, 2013, 1300, 226-235.	3.8	12
276	Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring. Digestive and Liver Disease, 2015, 47, 1027-1032.	0.9	12
277	Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease. Digestive and Liver Disease, 2017, 49, 978-983.	0.9	12
278	Current and future perspectives in the management of gastroesophageal reflux disease. Annals of the New York Academy of Sciences, 2018, 1434, 70-83.	3.8	12
279	Effects of bariatric surgery on the esophagus. Current Opinion in Gastroenterology, 2018, 34, 243-248.	2.3	12
280	Faecal Microbiome Transplantation as a Solution to Chronic Enteropathies in Dogs: A Case Study of Beneficial Microbial Evolution. Animals, 2021, 11, 1433.	2.3	12
281	Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation. Intestinal Research, 2022, 20, 114-123.	2.6	12
282	Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study. Digestive Diseases, 2021, 39, 16-24.	1.9	12
283	Proton Pump Inhibitor Failure: Why Does It Occur and How Can It Be Managed?. Digestion, 2006, 73, 215-217.	2.3	11
284	RE: A Simple Technique to Restore Needle Patency During Percutaneous Lavage and Aspiration of Calcific Rotator Cuff Tendinopathy. PM and R, 2013, 5, 633-633.	1.6	11
285	Optimal management of constipation associated with irritable bowel syndrome. Therapeutics and Clinical Risk Management, 2015, 11, 691.	2.0	11
286	Current treatment options for esophageal diseases. Annals of the New York Academy of Sciences, 2016, 1381, 139-151.	3.8	11
287	Nonerosive reflux disease: clinical concepts. Annals of the New York Academy of Sciences, 2018, 1434, 290-303.	3.8	11
288	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Digestive and Liver Disease, 2020, 52, 862-868.	0.9	11

#	ARTICLE	IF	CITATIONS
289	Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9950.	4.1	11
290	Clinical, endoscopic, histological and radiological characteristics of Italian patients with eosinophilic oesophagitis. <i>Digestive and Liver Disease</i> , 2015, 47, 1033-1038.	0.9	10
291	Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. <i>Autoimmunity Reviews</i> , 2016, 15, 1208-1209.	5.8	10
292	What to eat and drink in the festive season. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 608-614.	1.6	10
293	The treatment of achalasia patients with esophageal varices: an international study. <i>United European Gastroenterology Journal</i> , 2019, 7, 565-572.	3.8	10
294	Advancements in the use of manometry and impedance testing for esophageal functional disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 425-435.	3.0	10
295	Esophagogastric junction function and gastric pressure profile after minigastric bypass compared with Billroth II. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 567-574.	1.2	10
296	Factors associated with disability in patients with ulcerative colitis: A cross-sectional study. <i>Journal of Digestive Diseases</i> , 2020, 21, 81-87.	1.5	10
297	Esophagogastric junction morphology and contractile integral on high-resolution manometry in asymptomatic healthy volunteers: An international multicenter study. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14009.	3.0	10
298	Ciclosporin or Infliximab as Rescue Therapy in Acute Glucocorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 733-741.	1.3	10
299	A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110314.	3.2	10
300	Esophageal level reflux characteristics: How experienced reviewers differentiate true reflux from artifact on pH-impedance studies. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14153.	3.0	10
301	Reflux characteristics triggering post-reflux swallow-induced peristaltic wave (PSPW) in patients with GERD symptoms. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14183.	3.0	10
302	Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. <i>Digestive and Liver Disease</i> , 2022, 54, 1367-1373.	0.9	10
303	The Role of Acid in Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2011, 106, 1168.	0.4	9
304	Endotherapy for and tailored approaches to treating GERD, and refractory GERD. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 166-186.	3.8	9
305	Sleeve Gastrectomy, GERD, and Barrett's Esophagus: It Is Time for Objective Testing. <i>Obesity Surgery</i> , 2019, 29, 2312-2313.	2.1	9
306	Opioid Treatment and Excessive Alcohol Consumption Are Associated With Esophagogastric Junction Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 205-211.	2.4	9

#	ARTICLE	IF	CITATIONS
307	The hypercontractile esophagus: Still a tough nut to crack. <i>Neurogastroenterology and Motility</i> , 2020, 32, e14010.	3.0	9
308	Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2790-2792.e1.	3.8	9
309	Development of quality indicators for the diagnosis and management of achalasia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14118.	3.0	9
310	Noncoding RNAs as drivers of the phenotypic plasticity of oesophageal mucosa. <i>World Journal of Gastroenterology</i> , 2017, 23, 7653-7656.	3.3	9
311	Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors. <i>World Journal of Gastrointestinal Surgery</i> , 2016, 8, 719.	1.5	9
312	Is there a role for high resolution manometry in GERD diagnosis?. <i>Minerva Gastroenterology</i> , 2017, 63, 235-248.	0.5	9
313	Rapid Drink Challenge During High-resolution Manometry for Evaluation of Esophageal Emptying in Treated Achalasia. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 55-63.	4.4	9
314	The present and future of gastroenterology and hepatology: an international SWOT analysis (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	8.1	9
315	Twenty-four Hour Control of Gastric Acidity by Twice-Daily Doses of Placebo, Nizatidine 150 mg, Nizatidine 300 mg, and Ranitidine 300 mg. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 70-74.	2.0	8
316	Step-Up Empiric Elimination Diet for Pediatric and Adult Eosinophilic Esophagitis: The 2-4-6 Study. <i>Gastroenterology</i> , 2017, 152, S207.	1.3	8
317	Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. <i>Gut</i> , 2021, 70, 1241-1243.	12.1	8
318	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2914.	2.4	8
319	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 253-264.	3.7	8
320	Salivary microbiota composition may discriminate between patients with eosinophilic oesophagitis (<scp>EoE</scp>) and <scp>non-EoE</scp> subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 450-462.	3.7	8
321	The sensory system of the esophagusâ€“what do we know?. <i>Annals of the New York Academy of Sciences</i> , 2016, 1380, 91-103.	3.8	7
322	The contribution of intraepithelial inflammatory cells to the histological diagnosis of microscopic esophagitis. <i>Esophagus</i> , 2016, 13, 80-87.	1.9	7
323	A modification of Nissen fundoplication improves patients' outcome and may reduce procedure-related failure rate. <i>International Journal of Surgery</i> , 2017, 38, 83-89.	2.7	7
324	Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093458.	3.2	7

#	ARTICLE	IF	CITATIONS
325	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. <i>Biomedicines</i> , 2021, 9, 318.	3.2	7
326	Patients With Definite and Inconclusive Evidence of Reflux According to Lyon Consensus Display Similar Motility and Esophagogastric Junction Characteristics. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 565-573.	2.4	7
327	Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110233.	3.2	7
328	Usefulness of Pep-Test for Laryngo-Pharyngeal Reflux: A Pilot Study in Primary Care. <i>Korean Journal of Family Medicine</i> , 2020, 41, 250-255.	1.2	7
329	Duration of Acid Suppression in H ₂ -Antagonist Nonresponders. <i>Digestion</i> , 1992, 51, 185-192.	2.3	6
330	Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 11-28.	3.8	6
331	Light microscopy is useful to better define NERD and functional heartburn. <i>Gut</i> , 2014, 63, 368-368.	12.1	6
332	Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2015, 110, 472-473.	0.4	6
333	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1220-1225.	1.5	6
334	Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2397-2402.	2.3	6
335	Duodenal Histological Findings and Risk of Coeliac Disease in Subjects with Autoimmune Atrophic Gastritis: A Retrospective Evaluation. <i>Digestion</i> , 2021, 102, 615-621.	2.3	6
336	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e134-e136.	1.9	6
337	Faecal microbiota transplantation in <i>Clostridioides difficile</i> infection: real-life experience from an academic Italian hospital. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093431.	3.2	6
338	Immunolocalization of leptin and leptin receptor in colorectal mucosa of ulcerative colitis, Crohn's disease and control subjects with no inflammatory bowel disease. <i>Cell and Tissue Research</i> , 2021, 383, 1103-1122.	2.9	6
339	Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 91-97.	1.3	6
340	Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 17155.	3.3	6
341	The tapestry of reflux syndromes: translating new insight into clinical practice. <i>British Journal of General Practice</i> , 2021, 71, 470-473.	1.4	6
342	Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14279.	3.0	6

#	ARTICLE	IF	CITATIONS
343	The â€œDICAâ€•Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 23-27.	0.9	6
344	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.5	6
345	Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1473-1482.	2.3	5
346	Weight Loss Is Truly Effective in Reducing Symptoms and Proton Pump Inhibitor Use in Patients With Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2023.	4.4	5
347	Novel insights into esophageal diagnostic procedures. <i>Annals of the New York Academy of Sciences</i> , 2016, 1380, 162-177.	3.8	5
348	Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 569-574.	3.4	5
349	Gastrointestinal: An unusual rectal finding in a patient with ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 179-179.	2.8	5
350	Development of a Preliminary Question Prompt List as a Communication Tool for Adults With Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 857-863.	2.2	5
351	Starting a Biologic Therapy in IBD Patients Amid COVID-19: Hold, Careful Monitoring, or Testing?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1785-1785.	1.3	5
352	Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases. <i>Scientific Reports</i> , 2021, 11, 15251.	3.3	5
353	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 940-945.	1.3	5
354	Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1845-1852.	1.3	5
355	Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. <i>Updates in Surgery</i> , 2023, 75, 291-303.	2.0	5
356	Real-time determination of gastric juice pH with EndoFasterÂ® for atrophic gastritis assessment. <i>Digestive and Liver Disease</i> , 2022, 54, 1646-1648.	0.9	5
357	Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor. <i>Digestive and Liver Disease</i> , 2005, 37, 454-457.	0.9	4
358	Barrett's esophagus: surgical treatments. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 175-195.	3.8	4
359	Functional aspects of distal oesophageal spasm: The role of onset velocity and contraction amplitude on bolus transit. <i>Digestive and Liver Disease</i> , 2012, 44, 569-575.	0.9	4
360	Efficacy of teduglutide in a patient with Crohnâ€™s disease and short bowel syndrome on enteral nutrition: letâ€™s start to think out of the box. <i>Gastroenterology Report</i> , 2019, 7, 459-460.	1.3	4

#	ARTICLE	IF	CITATIONS
361	A Survey on Nutritional Knowledge in Coeliac Disease Compared to Inflammatory Bowel Diseases Patients and Healthy Subjects. <i>Nutrients</i> , 2020, 12, 1110.	4.1	4
362	The coeliac stomach: A review of the literature. <i>Digestive and Liver Disease</i> , 2020, 52, 615-624.	0.9	4
363	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, , 1-10.	3.0	4
364	Influence of <i>Tilia tomentosa</i> Moench Extract on Mouse Small Intestine Neuromuscular Contractility. <i>Nutrients</i> , 2021, 13, 3505.	4.1	4
365	Biliary Tree Diagnostics: Advances in Endoscopic Imaging and Tissue Sampling. <i>Medicina (Lithuania)</i> , 2022, 58, 135.	2.0	4
366	Gastroesophageal reflux disease: key messages for clinicians. <i>Minerva Gastroenterology</i> , 2022, 67, .	0.5	4
367	Association between postprandial reflux swallow-induced peristaltic wave index and esophageal mucosal integrity in patients with GERD symptoms. <i>Neurogastroenterology and Motility</i> , 2023, 35, e14344.	3.0	4
368	Integrated Relaxation Pressure Classification and Probe Positioning Failure Detection in High-Resolution Esophageal Manometry Using Machine Learning. <i>Sensors</i> , 2022, 22, 253.	3.8	4
369	Not All Autoimmune Gastritis Are Created the Same. <i>Gastroenterology Research</i> , 2021, 14, 348-349.	1.3	4
370	Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis. <i>Current Opinion in Pharmacology</i> , 2022, 65, 102264.	3.5	4
371	Is acid relevant in the genesis of dyspeptic symptoms associated with nonerosive reflux disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 252-254.	1.6	3
372	Small Intestinal Bacterial Overgrowth and <i>Helicobacter pylori</i> : Can They Be Cause of Thrombocytopenia in Patients With Chronic Liver Disease?. <i>American Journal of Gastroenterology</i> , 2011, 106, 1171-1172.	0.4	3
373	OC.06.1 USE OF A NON-INVASIVE PEPSIN DIAGNOSTIC TEST TO DETECT GERD: CORRELATION WITH MII-pH EVALUATION IN A SERIES OF SUSPECTED NERD PATIENTS. A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2013, 45, S68-S69.	0.9	3
374	Esophageal biopsies in the management of GERD: complementary tool for many but not for all. <i>Human Pathology</i> , 2014, 45, 2512-2513.	2.0	3
375	Letter: biological therapies are effective for prevention of postoperative Crohn's disease recurrence. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 322-322.	3.7	3
376	OC.02.5 DIFFERENT ACCURACY OF VARIOUS IMPEDANCE-PH NORMAL VALUES IN DIAGNOSING GERD IN PATIENTS WITH PROVEN OR HIGHLY SUSPECTED REFLUX DISEASE. <i>Digestive and Liver Disease</i> , 2014, 46, S8.	0.9	3
377	DOP057 The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF- α levels and clinical outcome. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S42.	1.3	3
378	Incidental physiological sliding hiatal hernia: a single center comparison study between CT with water enema and CT colonography. <i>Radiologia Medica</i> , 2015, 120, 683-689.	7.7	3

#	ARTICLE	IF	CITATIONS
379	956 Impairment of Chemical Clearance and Mucosal Integrity Distinguish Hypersensitive Esophagus From Functional Heartburn. <i>Gastroenterology</i> , 2016, 150, S189-S190.	1.3	3
380	Tu2007 Inflammatory Bowel Disease And Psychological Status: Determinants And Social Consequences. <i>Gastroenterology</i> , 2016, 150, S1004.	1.3	3
381	Caution About Overinterpretation of Number of Reflux Episodes in Reflux Monitoring for Refractory Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1060.	4.4	3
382	Comparison of computed tomography and magnetic resonance imaging in the discrimination of intraperitoneal and extraperitoneal rectal cancer: initial experience. <i>Clinical Imaging</i> , 2016, 40, 57-62.	1.5	3
383	Adalimumab Therapy Rather than Azathioprine and Mesalamine is Able to Halt Crohn's Disease Progression after Resective Surgery and a Post-Hoc Analysis of a Prospective Randomized Study. <i>Gastroenterology</i> , 2017, 152, S774.	1.3	3
384	An "Old" Esophagus. <i>American Journal of Gastroenterology</i> , 2020, 115, 1389-1389.	0.4	3
385	The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?. <i>Gastroenterology</i> , 2021, 160, 1903-1904.	1.3	3
386	Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 25-29.	0.9	3
387	Diagnostic yield and reliability of postprandial high-resolution manometry and impedanceph for detecting rumination and supragastric belching in PPI nonresponders. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14106.	3.0	3
388	Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	1.6	3
389	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 939-944.	2.8	3
390	Question Prompt List as a Communication Tool for Adults With Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 565-570.	2.2	3
391	<i>Helicobacter pylori</i> and tolerance to H2-blockers. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 289-290.	3.7	2
392	The Relevance of Weakly Acidic Reflux in Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, e21-e22.	1.3	2
393	Nonerosive reflux disease and functional heartburn are clearly separate entities. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 749-750.	1.6	2
394	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 129-130.	2.4	2
395	Letter: treatment for small intestinal bacterial overgrowth " where are we now?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 442-442.	3.7	2
396	P505 ELISA vs. HMSA: a comparison between two different methods for the evaluation of adalimumab serum concentration and anti-adalimumab antibodies " Preliminary data. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S278.	1.3	2

#	ARTICLE	IF	CITATIONS
397	An Unusual Cutaneous Manifestation in a Patient With Cystic Fibrosis. <i>Gastroenterology</i> , 2014, 147, e10-e11.	1.3	2
398	Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 292-293.	2.4	2
399	Data on Symptom Association Analysis in Patients Undergoing Endoscopic Therapy Is Useful to Better Define a Successful Therapeutic Approach. <i>American Journal of Gastroenterology</i> , 2015, 110, 1621.	0.4	2
400	Fecal calprotectin in systemic sclerosis: Light and shade of a promising tool. <i>Autoimmunity Reviews</i> , 2016, 15, 1206-1207.	5.8	2
401	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1245-1245.	3.7	2
402	It is Time to Re-Think the Role of Small Intestinal Bacterial Overgrowth in IBS Patients. <i>American Journal of Gastroenterology</i> , 2016, 111, 1364.	0.4	2
403	Symptom perception in patients with NERD: do nerves matter?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 634-636.	17.8	2
404	A modified Nissen fundoplication: subjective and objective midterm results. <i>Langenbeck's Archives of Surgery</i> , 2018, 403, 279-287.	1.9	2
405	Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 107-108.	3.7	2
406	Gastric fundal splenosis presenting as a stromal tumor and diagnosed by endoscopic ultrasound-guided SharkCore biopsy. <i>Endoscopy</i> , 2019, 51, E160-E161.	1.8	2
407	P475 Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF- α maintenance therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S349-S350.	1.3	2
408	P655 Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with inflammatory bowel disease mimicking prebiotic activity and proving effects on the treatment of the disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S446-S447.	1.3	2
409	Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00061.	2.5	2
410	Diagnosis and Outcome of Oesophageal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 624-629.	1.3	2
411	P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn's disease refractory or intolerant to anti-TNF: a multicentre Italian study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S379-S379.	1.3	2
412	There is much more to rely on histology than the sole endoscopy tells us. <i>Gut</i> , 2020, 69, 1709-1710.	12.1	2
413	Editorial: symptom improvement does not equal satisfaction with treatment for constipation—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 910-911.	3.7	2
414	Global Prevalence of Chronic Idiopathic Constipation According to the Rome Criteria: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2

#	ARTICLE	IF	CITATIONS
415	Objective Evidence of Gastro-Esophageal Reflux Disease is Rare in Patients with Autoimmune Gastritis. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 30-36.	0.9	2
416	Eosinophilic Esophagitis and Achalasia: Are We Putting All the Pieces Together?. American Journal of Gastroenterology, 2021, 116, 1759-1759.	0.4	2
417	Manometric pattern progression in esophageal achalasia in the era of high-resolution manometry. Annals of Translational Medicine, 2021, 9, 906-906.	1.7	2
418	Editorial: inconclusive diagnosis of GERD: are new parameters in impedance-pHmetry ready for clinical use? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 498-499.	3.7	2
419	Exploring the association between esophageal mucosal inflammation, impaired motility, and GERD severity. Neurogastroenterology and Motility, 2021, 33, e14211.	3.0	2
420	Nonachalasic esophageal motor disorders, from diagnosis to therapy. Expert Review of Gastroenterology and Hepatology, 2022, 16, 205-216.	3.0	2
421	Letter: the potential link between oesophageal hypervigilance, visceral anxiety, increased swallow rate and oesophageal mucosal integrity. Alimentary Pharmacology and Therapeutics, 2022, 55, 756-757.	3.7	2
422	Mismatch repair status and gastroesophageal dysplasia: need for a dedicated gastrointestinal pathologist?. Histopathology, 2022, , .	2.9	2
423	Relevance of Excessive Air Swallowing in GERD Patients With Concomitant Functional Dyspepsia and Poor Response to PPI Therapy. Journal of Clinical Gastroenterology, 2023, 57, 466-471.	2.2	2
424	Automated Chicago Classification for Esophageal Motility Disorder Diagnosis Using Machine Learning. Sensors, 2022, 22, 5227.	3.8	2
425	Pharmacodynamic studies on PPIs: Look carefully at the country of origin. Digestive and Liver Disease, 2006, 38, 808-810.	0.9	1
426	Gastroesophageal Reflux and Lung Disease in Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1167-1168.	5.6	1
427	Nocturnal reflux and sleep disturbances: An overlooked link in the past. Digestive and Liver Disease, 2011, 43, 755-756.	0.9	1
428	The reason for failure of on-demand PPI therapy in NERD patients. Neurogastroenterology and Motility, 2011, 23, 811-811.	3.0	1
429	The relevance of symptom association analysis in GORD patients undergoing anti-reflux surgery. Gut, 2012, 61, 326.1-326.	12.1	1
430	It is time to plan clinical trials on true NERD patients. Neurogastroenterology and Motility, 2012, 24, 885-886.	3.0	1
431	Esophageal acid exposure still plays a major role in patients with NERD. Journal of Gastroenterology, 2013, 48, 552-553.	5.1	1
432	Comment to "Predictors of clinical response of acid suppression in Chinese patients with gastroesophageal reflux disease". Digestive and Liver Disease, 2013, 45, 868-869.	0.9	1

#	ARTICLE	IF	CITATIONS
433	Letter: symptom indexes in reflux monitoring â€two are better than one. Alimentary Pharmacology and Therapeutics, 2013, 37, 918-918.	3.7	1
434	OC.02.2 REFLUX PATTERN AND ROLE OF IMPEDANCE-PH VARIABLES IN PREDICTING PPI RESPONSE IN PATIENTS WITH SUSPECTED GERD-RELATED CHRONIC COUGH. Digestive and Liver Disease, 2014, 46, S7.	0.9	1
435	Symptom analysis improves GERD diagnosis and may be helpful to define a successful surgical approach. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 698-699.	2.4	1
436	Not all anti-reflux treatment failures are due to persistence of abnormal esophageal acid exposure. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1382-1383.	2.4	1
437	The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. Journal of Gastroenterology, 2014, 49, 1362-1363.	5.1	1
438	P.10.26 DISTAL AND PROXIMAL ESOPHAGEAL IMPEDANCE BASAL VALUES IN PATIENTS WITH NON-EROSIVE REFLUX DISEASE AND FUNCTIONAL HEARTBURN. Digestive and Liver Disease, 2014, 46, S93.	0.9	1
439	A More In-depth Evaluation of Impedance-pH Could Assist in Distinguishing Reflux-related From Reflux-unrelated Heartburn. Journal of Neurogastroenterology and Motility, 2015, 21, 621-622.	2.4	1
440	Antiâ€Tumor Necrosis Factor Antibodies for Prevention of Crohnâ€™s Disease Recurrence After Surgery: More Than a Hope. Clinical Gastroenterology and Hepatology, 2015, 13, 1856.	4.4	1
441	Tricyclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. American Journal of Gastroenterology, 2016, 111, 1037-1038.	0.4	1
442	P.07.14 BIOLOGICAL THERAPY IS ABLE TO MODIFY THE DISEASE PROGRESSION OF CROHN'S DISEASE PREVENTING ITS LONG-TERM ASSOCIATED DISABILITY â€ A STUDY PERFORMED USING THE LÃ‰MANN SCORE. Digestive and Liver Disease, 2016, 48, e162-e163.	0.9	1
443	Mo1173 Association Between Eosinophilic Esophagitis and Helicobacter pylori Infection: Preliminary Results of a Multicenter Study. Gastroenterology, 2016, 150, S657-S658.	1.3	1
444	Tu2009 Does LÃ‰mann Index Reflect the Quality of Life in Crohn Disease Patients on Treatment With Biological Therapy?. Gastroenterology, 2016, 150, S1004-S1005.	1.3	1
445	Barrett's esophagus detection: Multiple biopsies are useful, even better if you have an â€œXâ€ on your map. Digestive and Liver Disease, 2016, 48, 1041-1042.	0.9	1
446	The Natural History of Achalasia: Evidence of a Continuum and the Pattern-Evolutive Staging Theory. Gastroenterology, 2017, 152, S702-S703.	1.3	1
447	High Resolution Manometry is Superior to Endoscopy and Radiology in Assessing and Grading Sliding Hiatal Hernia. A Prospective Comparison with Surgical in vivo. Gastroenterology, 2017, 152, S3.	1.3	1
448	The Effect of Bile Reflux on Baseline Impedance Value and Chemical Clearance in Patients with NERD. Gastroenterology, 2017, 152, S654.	1.3	1
449	Gastrin 17 in Singling Out Patients with Different Patterns of Refluxate: A Pilot Study Using Impedance-pH as Reference Standard. Gastroenterology, 2017, 152, S653.	1.3	1
450	Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 2017, 23, 318-319.	2.4	1

#	ARTICLE	IF	CITATIONS
451	P.07.11 LOW FODMAP DIET IMPROVE DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Digestive and Liver Disease, 2018, 50, e197-e198.	0.9	1
452	P.06.2 PROTON PUMP INHIBITOR THERAPY IMPROVES ESOPHAGEAL SYMPTOMS BY RESTORING A NORMAL ESOPHAGEAL PERISTALSIS IN PPI-REE. Digestive and Liver Disease, 2018, 50, e179.	0.9	1
453	P.07.3 EFFECTIVENESS OF GOLIMUMAB IN REAL LIFE – A SINGLE CENTER PROSPECTIVE STUDY. Digestive and Liver Disease, 2018, 50, e193-e194.	0.9	1
454	P.06.5 ESOMEPRAZOLE, RABEPRAZOLE AND PANTOPRAZOLE ARE EQUALLY EFFECTIVE IN INDUCING ENDOSCOPIC AND HISTOLOGIC REMISSION IN PATIENTS WITH PROTON PUMP INHIBITOR-RESPONSE ESOPHAGEAL EOSINOPHILIA. Digestive and Liver Disease, 2018, 50, e180-e181.	0.9	1
455	The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. Expert Review of Clinical Pharmacology, 2019, 12, 1011-1012.	3.1	1
456	P697 <i>Pneumocystis jirovecii</i> pneumonia in IBD patients treated with immunomodulator(s). Journal of Crohn's and Colitis, 2019, 13, S468-S469.	1.3	1
457	P650 Mechanisms of Infliximab failure: the predictive role of MMP3. Journal of Crohn's and Colitis, 2019, 13, S444-S444.	1.3	1
458	A further step forward in our knowledge of the pathogenetic role of gastroesophageal reflux in pulmonary fibrosis. Digestive and Liver Disease, 2020, 52, 986-987.	0.9	1
459	Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nunc. Digestive and Liver Disease, 2020, 52, 1248-1249.	0.9	1
460	Tu1336 REFLUX MONITORING WITH IMPEDANCE-PHMETRY: NEW SET OF NORMAL VALUES OBTAINED FROM CONSENSUS ANALYSIS OF TRACINGS FROM HEALTHY ASYMPTOMATIC SUBJECTS. A MULTICENTRE INTERNATIONAL COLLABORATIVE STUDY. PRELIMINARY RESULTS. Gastroenterology, 2020, 158, S-1064-S-1065.	1.3	1
461	T01.02.21 ESOPHAGEAL MOTILITY DISORDERS IN EOSINOPHILIC ESOPHAGITIS. Digestive and Liver Disease, 2020, 52, S71-S72.	0.9	1
462	No need of transforming gastroenterology units to covid units at the time of SARS-COV2 infection - a single-center analysis from northern Italy. Digestive and Liver Disease, 2020, 52, 1094-1096.	0.9	1
463	Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF. Inflammatory Bowel Diseases, 2020, 26, e104-e104.	1.9	1
464	P468 Switching from adalimumab originator to ABP 501 biosimilar: a multicentre North Italian study. Journal of Crohn's and Colitis, 2020, 14, S414-S414.	1.3	1
465	A Peculiar Cutaneous Manifestation in a Patient With Crohn's Disease. Gastroenterology, 2021, 160, e1-e3.	1.3	1
466	Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment?. Gastroenterology, 2021, 160, 2626-2627.	1.3	1
467	Bariatric Surgery and Esophageal Function: An Eternal Impasse?. American Journal of Gastroenterology, 2021, 116, 1754-1755.	0.4	1
468	DOP79 Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case Series. Journal of Crohn's and Colitis, 2021, 15, S111-S111.	1.3	1

#	ARTICLE	IF	CITATIONS
469	Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak. <i>Journal of Clinical Medicine</i> , 2021, 10, 3270.	2.4	1
470	How a modified Nissen procedure works: a mechanistic study using intraoperative esophageal high-resolution manometry. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	1.9	1
471	Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 974-975.	3.7	1
472	Complexity and diversity of gastroesophageal reflux disease phenotypes. <i>Minerva Gastroenterology</i> , 2017, 63, 198-204.	0.5	1
473	Development and Validation of a Multi-marker Serum Test for the Assessment of Mucosal Healing in Crohn's Disease Patients. <i>American Journal of Gastroenterology</i> , 2017, 112, S324.	0.4	1
474	Vonoprazan May Provide Better Results than PPIs in Helicobacter Pylori Eradication and Beyond – Is it Time for a Change?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 375-377.	0.9	1
475	Toward a potential association between eosinophilic esophagitis and Klinefelter syndrome: a case series and review of the literature. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210768.	3.2	1
476	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series. <i>Pathology Research and Practice</i> , 2022, 233, 153872.	2.3	1
477	Small intestine neuromuscular dysfunction in a mouse model of dextran sulfate sodium-induced ileitis: Involvement of dopaminergic neurotransmission. <i>Life Sciences</i> , 2022, 301, 120562.	4.3	1
478	Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14416.	3.0	1
479	Advances on Neurogastroenterology and Motility Disorders: Pathophysiology, Diagnostics and Management. <i>Journal of Clinical Medicine</i> , 2022, 11, 2911.	2.4	1
480	PA.3 PREVALENCE OF DYSPESIA SYMPTOMS IN PATIENTS WITH NON EROSION REFLUX DISEASE (NERD) SUBCLASSIFIED USING 24-HOUR AMBULATORY INTRALUMINAL PH-IMPEDANCE. <i>Digestive and Liver Disease</i> , 2008, 40, S76-S77.	0.9	0
481	PA.132 FINDINGS AFTER ULTRASOUND-GUIDED FINE NEEDLE AGO-BIOPSY (FNAB) IN SUSPECTED PANCREATIC LESIONS. <i>Digestive and Liver Disease</i> , 2008, 40, S123.	0.9	0
482	PA.181 PREDICTABLE BOLUS RETENTION SITE ALONG THE ESOPHAGUS IN PATIENTS WITH ESOPHAGEAL SYMPTOMS: STUDIES USING COMBINED IMPEDANCE-MANOMETRY TESTING. <i>Digestive and Liver Disease</i> , 2008, 40, S142.	0.9	0
483	PA.243 CONVENTIONAL CONTRAST-ENHANCED ULTRASONOGRAPHY (CEUS) VERSUS SIDE-BY-SIDE CEUS IN THE ASSESSMENT OF DIFFICULT LIVER LESIONS. <i>Digestive and Liver Disease</i> , 2008, 40, S164.	0.9	0
484	LACTULOSE BREATH TEST IS A NON-INVASIVE TOOL TO ASSESS ESOPHAGEAL INVOLVEMENT IN SCLERODERMA PATIENTS. <i>Digestive and Liver Disease</i> , 2009, 41, S44.	0.9	0
485	NONACID REFLUX IS ABLE TO DETERMINE MICROSCOPIC ESOPHAGITIS IN NON-EROSIVE REFLUX DISEASE (NERD) PATIENTS. <i>Digestive and Liver Disease</i> , 2009, 41, S64.	0.9	0
486	REFLUX AND DYSPETIC SYMPTOM PATTERNS IN PATIENTS WITH NON EROSION REFLUX DISEASE (NERD) SUBCLASSIFIED USING 24-HOUR AMBULATORY INTRALUMINAL pH-IMPEDANCE. <i>Digestive and Liver Disease</i> , 2009, 41, S65.	0.9	0

#	ARTICLE	IF	CITATIONS
487	DEMOGRAPHIC AND CLINICAL FEATURES HELP TO IDENTIFY NON EROSIIVE REFLUX DISEASE (NERD) PATIENTS WITH ABNORMAL pH-IMPEDANCE TESTING. Digestive and Liver Disease, 2009, 41, S77.	0.9	0
488	GASTROINTESTINAL ASSESSMENT IN A LARGE COHORT OF PATIENTS SUFFERING FROM SYSTEMIC SCLEROSIS. Digestive and Liver Disease, 2009, 41, S140-S141.	0.9	0
489	Emerging Factors of Survival in Usual Interstitial Pneumonia and Nonspecific Interstitial Pneumonia. Chest, 2010, 138, 534A.	0.8	0
490	OC.08.2 MICROSCOPIC ESOPHAGITIS IS MORE FREQUENT IN PATIENTS WITH PH-POSITIVE NON-EROSIVE REFLUX DISEASE AND HYPERSENSITIVE ESOPHAGUS THAN IN THOSE WITH FUNCTIONAL HEARTBURN: A STUDY USING IMPEDANCE-pH AND OPTICAL MICROSCOPY. Digestive and Liver Disease, 2010, 42, S89.	0.9	0
491	P.11 IS NONACID ACIDIC REFLUX INCREASED IN CHOLECYSTECTOMIZED PATIENTS WITH TYPICAL REFLUX SYMPTOMS? A STUDY USING IMPEDANCE-pH MONITORING. Digestive and Liver Disease, 2010, 42, S106.	0.9	0
492	P.14 PREVALENCE OF ESOPHAGEAL MOTILITY ABNORMALITIES IN PATIENTS WITH â€œTRUEâ€•NON-EROSIVE REFLUX DISEASE, EROSIIVE ESOPHAGITIS, BARRETT ESOPHAGUS AND FUNCTIONAL HEARTBURN. Digestive and Liver Disease, 2010, 42, S107.	0.9	0
493	P.18 SYMPTOM ASSOCIATION PROBABILITY FOR ACID AND NONACID REFLUX IN PATIENTS WITH EROSIIVE ESOPHAGITIS (EE) AND NON-EROSIVE REFLUX DISEASE (NERD). Digestive and Liver Disease, 2010, 42, S109.	0.9	0
494	P.49 ULTRASOUND EVALUATION OF THE POSTERIOR COMPARTMENT OF THE FEMALE PELVIC FLOOR: TRANS-LABIAL ASSESSMENT OF NORMAL ANATOMY AND PATHOLOGIC CONDITIONS. Digestive and Liver Disease, 2010, 42, S120-S121.	0.9	0
495	Gastroesophageal Reflux is More Relevant Than Motor Dysfunction in Provoking Non-Cardiac Chest Pain. Gastroenterology, 2011, 140, S-251-S-252.	1.3	0
496	OC.03.5: REFLUX PATTERNS DIFFER AMONG PATIENTS WITH NON-EROSIVE REFLUX DISEASE (NERD), HYPERSENSITIVE ESOPHAGUS (HE) AND FUNCTIONAL HEARTBURN (FH). Digestive and Liver Disease, 2011, 43, S124-S125.	0.9	0
497	OC.03.6: PREVALENCE OF ESOPHAGEAL MOTILITY ABNORMALITIES IN PATIENTS WITH â€œTRUEâ€•NON-EROSIVE REFLUX DISEASE, EROSIIVE ESOPHAGITIS, BARRETT ESOPHAGUS AND FUNCTIONAL HEARTBURN. Digestive and Liver Disease, 2011, 43, S125.	0.9	0
498	P.1.37: GASTROESOPHAGEAL REFLUX IS MORE RELEVANT THAN ESOPHAGEAL MOTOR DYSFUNCTION IN PROVOKING NON-CARDIAC CHEST PAIN IN ENDOSCOPY-NEGATIVE PATIENTS. Digestive and Liver Disease, 2011, 43, S160.	0.9	0
499	P.1.44: PREVALENCE OF NON-POLYPOID LATERALLY SPREADING TUMORS (LST) AND ROLE OF MUCOSECTOMY IN THEIR REMOVAL: OUR EXPERIENCE. Digestive and Liver Disease, 2011, 43, S163.	0.9	0
500	P.1.69: PREVALENCE OF SERRATED ADENOMAS IN PATIENTS WHO UNDERWENT PAN-COLONOSCOPY: A RETROSPECTIVE STUDY. Digestive and Liver Disease, 2011, 43, S171.	0.9	0
501	P.1.106: DIFFERENCES IN REFLUX CHARACTERISTICS CAN BE DIAGNOSTIC IN NERD PATIENTS WHEN SYMPTOMS DO NOT OCCUR DURING MII-PH TESTING. Digestive and Liver Disease, 2011, 43, S183.	0.9	0
502	P.1.201: CAN WE ESTIMATE ORO-CECAL TRANSIT TIME USING MRI? A COMPARISON WITH HYDROGEN BREATH TEST (H2-BT) IN HEALTHY VOLUNTEERS. Digestive and Liver Disease, 2011, 43, S214-S215.	0.9	0
503	Comment to â€œCurrent applications of evolving methodologies in gastroesophageal reflux disease testingâ€• Digestive and Liver Disease, 2011, 43, 835.	0.9	0
504	Impedance-pH Monitoring Increases the Diagnostic Yield in Endoscopic Negative Patients With Non-Cardiac Chest Pain. Gastroenterology, 2011, 140, S-247-S-248.	1.3	0

#	ARTICLE	IF	CITATIONS
505	The Differing Role of Overweight Among the Various Subgroups of Non-Erosive Reflux Disease. <i>Gastroenterology</i> , 2011, 140, S-627.	1.3	0
506	Can We Estimate Oro-Cecal Transit Time Using Magnetic Resonance Imaging (MRI)? A Comparison With Hydrogen Breath Test (H2-BT) in Healthy Volunteers. <i>Gastroenterology</i> , 2011, 140, S-446.	1.3	0
507	P.1.253: METHANE PRODUCTION ASSESSED BY GLUCOSE BREATH TEST IS ASSOCIATED WITH FUNCTIONAL CONSTIPATION HABIT. <i>Digestive and Liver Disease</i> , 2011, 43, S232.	0.9	0
508	The Relevance of Reflux Monitoring Off Therapy. <i>American Journal of Gastroenterology</i> , 2011, 106, 1558-1559.	0.4	0
509	Studies on factors predicting GORD response to proton-pump inhibitors: NERD subpopulations need to be analysed separately. <i>Gut</i> , 2012, 61, 1368.2-1369.	12.1	0
510	The importance of subgrouping refractory NERD patients according to esophageal pH-impedance testing. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 3503-3504.	2.4	0
511	Non-erosive reflux disease patients are more complex than the sole endoscopy tells us. <i>Clinical Oral Investigations</i> , 2013, 17, 1965-1966.	3.0	0
512	Symptom association analysis is important in GERD patients undergoing endoscopic therapy. <i>Gastrointestinal Endoscopy</i> , 2013, 77, 832.	1.0	0
513	Tu1805 Different Accuracy of Various Impedance-pH Normal Values in Diagnosing GERD in Patients With Proven Reflux Disease. <i>Gastroenterology</i> , 2013, 144, S-850-S-851.	1.3	0
514	Tu1771 Impedance-pH Explores With More Accuracy Than pH-Metry Alone the Relationship Between Aspiration of Gastric Contents and Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis. <i>Gastroenterology</i> , 2013, 144, S-840-S-841.	1.3	0
515	Non-Erosive Reflux Disease is More Complex Than Negative Endoscopy Only. <i>American Journal of Gastroenterology</i> , 2013, 108, 1657-1658.	0.4	0
516	Arterial congestive gastropathy: a new entity?. <i>Endoscopy</i> , 2014, 46, E397-E398.	1.8	0
517	P.10.21 PATIENTS WITH NEGATIVE IMPEDANCE AND PH WHO RESPOND TO ACID SUPPRESSION: ARE THEY HYPERSENSITIVE PATIENTS? A STUDY WITH BASELINE IMPEDANCE VALUES AND PSPW INDEX. <i>Digestive and Liver Disease</i> , 2014, 46, S91-S92.	0.9	0
518	P.13.17 INTRA- AND INTEROBSERVER AGREEMENT BETWEEN ENDOSCOPISTS AND PATHOLOGISTS FOR DETECTION OF GASTRIC INTESTINAL METAPLASIA BY MEANS OF NARROW BAND IMAGING WITH MAGNIFYING ENDOSCOPY. <i>Digestive and Liver Disease</i> , 2014, 46, S106.	0.9	0
519	P.10.22 EVALUATION OF SLEEP DISRUPTIONS BY MEANS OF IMPEDANCE-PH MONITORING IN PATIENTS WITH NERD. <i>Digestive and Liver Disease</i> , 2014, 46, S92.	0.9	0
520	PC.01.1 COMPARISON BETWEEN SOLID-STATE AND WATER-PERFUSED SYSTEM FOR THE DIAGNOSIS OF PRIMARY ESOPHAGEAL MOTILITY DISORDERS. <i>Digestive and Liver Disease</i> , 2014, 46, S1.	0.9	0
521	P656 Fcγ3 Receptor Type IIIa polymorphisms and their correlation with clinical outcome in patients with inflammatory bowel disease during a long term follow up. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S344.	1.3	0
522	Comment on "Impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [<i>Digestive and Liver Disease</i> 2014;46:596-602]. <i>Digestive and Liver Disease</i> , 2014, 46, 1052.	0.9	0

#	ARTICLE	IF	CITATIONS
523	OC.14.2 ASSESSMENT OF TOLERABILITY, DURATION AND COSTS OF SOLID-STATE AND WATER-PERFUSED SYSTEM DURING ESOPHAGEAL MOTILITY TESTING. Digestive and Liver Disease, 2014, 46, S32.	0.9	0
524	P.10.19 DIFFERENT IMPEDANCE-PH REFLUX PATTERNS IN SYMPTOMATIC CHOLECISTECTOMIZED AND NON-CHOLECISTECTOMIZED PATIENTS. Digestive and Liver Disease, 2014, 46, S91.	0.9	0
525	OC.18.4 CLINICAL AND ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH EOSINOPHILIC ESOPHAGITIS â€“ DATA FROM A SINGLE TERTIARY ITALIAN CENTER. Digestive and Liver Disease, 2014, 46, S39-S40.	0.9	0
526	Prevention of Crohnâ€™s Disease Recurrence After Surgery: On the Road to Recovery. Clinical Gastroenterology and Hepatology, 2014, 12, 1406.	4.4	0
527	Mo1128 Are Baseline Impedance Levels Assessed During Esophageal Impedance Manometry Helpful in Discriminating Patients With Gastroesophageal Reflux Disease From Those Without? A Pilot Study. Gastroenterology, 2015, 148, S-614-S-615.	1.3	0
528	Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis. Journal of Neurogastroenterology and Motility, 2016, 22, 710-711.	2.4	0
529	Sa1933 Biological Therapy Is Able to Halt Crohn's Disease Progression: A Prospective, Long Term Study Using the LÃ©Mann Index. Gastroenterology, 2016, 150, S408.	1.3	0
530	P.07.7 CROHN'S DISEASE IS A REAL TIME SENSITIVE EVOLUTIVE PATHOLOGY BASED ON LÃ©MANN INDEX? PRELIMINARY DATA FROM A TERTIARY PEDIATRIC IBD CENTER. Digestive and Liver Disease, 2016, 48, e160.	0.9	0
531	P.08.5 FEASIBILITY OF HIGH RESOLUTION IMPEDANCE MANOMETRY IN ASSESSING BARRETT'S ESOPHAGUS EXTENSION. Digestive and Liver Disease, 2016, 48, e166-e167.	0.9	0
532	Mo1191 The GerdQ Questionnaire Distinguishes Proton Pump Inhibitor-Responsive Esophageal Eosinophilia From Eosinophilic Esophagitis Patients. Gastroenterology, 2016, 150, S665.	1.3	0
533	Tu1975 Factors Predicting Clinical Relapse in Patients With Inflammatory Bowel Diseases During a Long-Term Follow-Up of 5 Years. Gastroenterology, 2016, 150, S995.	1.3	0
534	OC.05.8 ESOPHAGO-GASTRIC JUNCTION MORPHOLOGY VARIABILITY DURING STANDARD MANOMETRIC PROTOCOL AND AFTER ESOPHAGEAL STIMULATION AND BODY CHANGE POSITION â€“ PRELIMINARY RESULTS. Digestive and Liver Disease, 2016, 48, e90.	0.9	0
535	OC.12.1 ARE BASELINE IMPEDANCE LEVELS ASSESSED DURING ESOPHAGEAL IMPEDANCE MANOMETRY HELPFUL IN DISCRIMINATING PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE FROM THOSE WITHOUT? A PILOT STUDY. Digestive and Liver Disease, 2016, 48, e115.	0.9	0
536	P.08.12 GERDQ QUESTIONNAIRE DISTINGUISHES PROTON PUMP INHIBITOR-RESPONSIVE ESOPHAGEAL EOSINOPHILIA FROM EOSINOPHILIC ESOPHAGITIS PATIENTS. Digestive and Liver Disease, 2016, 48, e169.	0.9	0
537	Letter: proton pump inhibitorâ€™responsive oesophageal eosinophilia â€“ more than just gastroâ€™oesophageal reflux disease. Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 912-913.	3.7	0
538	173 Esophagogastric Junction Morphology Assessment by High Resolution Manometry and Its Relationship With Gastroesophageal Reflux Disease in Obese Patients Candidate to Bariatric Surgery. Gastroenterology, 2016, 150, S44.	1.3	0
539	Su1081 Which Is the Best Cut-off to Define Ineffective Esophageal Motility?. Gastroenterology, 2016, 150, S463.	1.3	0
540	PC.01.5 A NEW SUB-CLASSIFICATION OF ESOPHAGO-GASTRIC JUNCTION MORPHOLOGY TYPE I HELPS TO BETTER RECOGNIZE PATIENTS WITH A POSITIVE IMPEDANCE-PH MONITORING. Digestive and Liver Disease, 2016, 48, e69.	0.9	0

#	ARTICLE	IF	CITATIONS
541	OC.02.7 ADALIMUMAB TROUGH LEVELS AT WEEK EIGHT AS PREDICTIVE FACTOR OF LONG TERM CLINICAL REMISSION. Digestive and Liver Disease, 2016, 48, e77-e78.	0.9	0
542	P.08.3 BASELINE IMPEDANCE VALUES CAN REPRESENT A MARKER OF GASTROESOPHAGEAL REFLUX DISEASE AND ARE STRONGLY RELATED WITH THE DURATION OF THE DISEASE. Digestive and Liver Disease, 2016, 48, e165-e166.	0.9	0
543	OC.05.7 LARYNGOPHARYNGEAL SYMPTOMS IN PRIMARY CARE: USEFULNESS OF SALIVARY PEPSIN MEASUREMENT IN PREDICTING GERD. Digestive and Liver Disease, 2016, 48, e89.	0.9	0
544	Sa1312 Acid is the Key Factor Influencing Esophageal Mean Nocturnal Baseline Impedance but Not Post-reflux Swallow-Induced Peristaltic Wave Index in Gastro-Esophageal Reflux Disease. Gastroenterology, 2016, 150, S278-S279.	1.3	0
545	OC.07.1 REFRACTORY PATIENTS WITH NON-ACID REFLUX DISEASE AND THOSE WITH EROSION AND NON-EROSIVE REFLUX DISEASE HAVE SIMILAR RESPONSE TO ANTI-REFLUX SURGICAL THERAPY. Digestive and Liver Disease, 2016, 48, e95.	0.9	0
546	Sa1268 Feasibility of High Resolution Impedance Manometry in Assessing Barrett's Esophagus Extension. Gastroenterology, 2016, 150, S263-S264.	1.3	0
547	Sa1296 A Sub-classification of Esophago-Gastric Junction Morphology Type I May Be Useful To Better Recognize GERD Patients With a Positive Impedance-pH Monitoring. Gastroenterology, 2016, 150, S273.	1.3	0
548	P.07.15 INFILIXIMAB TROUGH LEVELS AND ANTI-DRUG ANTIBODIES AFTER INDUCTION AS PREDICTIVE FACTORS OF LONG TERM CLINICAL REMISSION. Digestive and Liver Disease, 2016, 48, e163.	0.9	0
549	OC.02.6 IDENTIFICATION OF A CUT-OFF FOR PERSISTENT ANTI-INFILIXIMAB ANTIBODIES AS A PREDICTOR OF RESPONSE TO INFILIXIMAB MONOTHERAPY. Digestive and Liver Disease, 2016, 48, e77.	0.9	0
550	P.08.10 ESOPHAGOGASTRIC JUNCTION MORPHOLOGY ASSESSMENT BY HIGH RESOLUTION MANOMETRY IN OBESE PATIENTS CANDIDATE TO BARIATRIC SURGERY. Digestive and Liver Disease, 2016, 48, e168.	0.9	0
551	P.08.16 NEW IMPEDANCE-PH PARAMETERS OF GASTRO-ESOPHAGEAL REFLUX DISEASE: A LESSON FROM PATIENTS WITH CHRONIC AUTOIMMUNE ATROPHIC GASTRITIS, NON-EROSIVE REFLUX DISEASE AND FUNCTIONAL HEARTBURN. Digestive and Liver Disease, 2016, 48, e171.	0.9	0
552	P.01.13: Gastrin-17 as a Non-Invasive Marker for Gerd: A Prospective Study on Sample of 777 Consecutive Patients. Digestive and Liver Disease, 2017, 49, e137.	0.9	0
553	Proximal Esophageal Baseline Impedance Levels are Able to Discriminate between Scleroderma Patients with and without Esophageal Involvement. Gastroenterology, 2017, 152, S654.	1.3	0
554	The Effect of Sleeve Gastrectomy on Esophageal Chemical Clearance and Basal Impedance Values. Gastroenterology, 2017, 152, S236.	1.3	0
555	OC.15.4: High Resolution Manometry Should be Considered the best Test to Diagnose Sliding Hiatal Hernia. Digestive and Liver Disease, 2017, 49, e121-e122.	0.9	0
556	Different Proton Pump Inhibitors are Equally Effective in Inducing Endoscopic and Histologic Remission in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. Gastroenterology, 2017, 152, S860-S861.	1.3	0
557	PWE-129â€¦Treatment of achalasia in patients with oesophageal varices: an international case series. , 2017, , .		0
558	P.02.1: Individual Assessment of Gastric Acid Production by Means of a Non-Invasive Test: Relationship Between Maximal Acid Output and Serum Pepsinogen I Levels in Patients with Different Upper GI Diseases. Digestive and Liver Disease, 2017, 49, e138.	0.9	0

#	ARTICLE	IF	CITATIONS
559	OC.15.1: High-Volume Rapid Drinking test Better Distinguishes Esophageal Body Inhibition Compared to Low-Volume Multiple Rapid Swallows. Digestive and Liver Disease, 2017, 49, e120-e121.	0.9	0
560	OC.15.2: Low-Volume Multiple Rapid Swallow Better Distinguishes Peristaltic Esophageal Reserve Compared to High-Volume Rapid Drinking Test. Digestive and Liver Disease, 2017, 49, e121.	0.9	0
561	P.01.11: Gastrin 17 in Singling out Patients with Different Pattern of Gastroesophageal Reflux: A Pilot Study using PH-Impedance as Reference Standard. Digestive and Liver Disease, 2017, 49, e136.	0.9	0
562	P.01.14: Overweight and Obesity as Risk Factors for Gerd Outcome: A 10 Years Study on a Gerd Population of 365 Patients. Digestive and Liver Disease, 2017, 49, e137.	0.9	0
563	P.11.10: Does LÃ©mann Index Reflect the Quality of Life in Crohnâ€™s Disease Patients on Treatment with Biological Therapy?. Digestive and Liver Disease, 2017, 49, e206.	0.9	0
564	High-Volume Rapid Drinking Test Better Distinguish Esophageal Body Inhibition Compared to Low-Volume Multiple Rapid Swallows. Gastroenterology, 2017, 152, S695.	1.3	0
565	P.01.12: The Abdominal Length of Lower Esophageal Sphincter is Inversely Correlated with Abnormal Esophageal Acid Exposure. Digestive and Liver Disease, 2017, 49, e136.	0.9	0
566	Vigor of Contraction is Directly Related to Esophageal Chemical Clearance (PSPW Index). Gastroenterology, 2017, 152, S654-S655.	1.3	0
567	Low-Volume Multiple Rapid Swallow Better Distinguish Peristaltic Esophageal Reserve Compared to High-Volume Rapid Drinking Test. Gastroenterology, 2017, 152, S694.	1.3	0
568	Low-FODMAP Diet Resulted Effective in Relieving Esophageal and Intestinal Symptoms in Patients with Pathophysiological Characteristics of Functional Heartburn and a Prospective, Interventional Study. Gastroenterology, 2017, 152, S751.	1.3	0
569	OC.15.5: Post-Reflux Swallow-Induced Peristaltic wave Index and Mean Nocturnal Baseline Impedance Predict Heartburn Response to Proton PUMP Inhibitors Better than Acid Exposure Time. Digestive and Liver Disease, 2017, 49, e122.	0.9	0
570	P.01.2: Changes in Esophageal Chemical Clearance and Basal Impedance Values after Sleeve Gastrectomy. Digestive and Liver Disease, 2017, 49, e131-e132.	0.9	0
571	P.01.4: The Effect of Bile Reflux on Baseline Impedance and Chemical Clearance in Patients with Nerd. Digestive and Liver Disease, 2017, 49, e132-e133.	0.9	0
572	P.01.6: Vigor of Contraction is Directly Related to Esophageal Chemical Clearance (PSPW Index). Digestive and Liver Disease, 2017, 49, e133-e134.	0.9	0
573	Post-Reflux Swallow-Induced Peristaltic Wave Index and Mean Nocturnal Baseline Impedance Predict Heartburn Response to Proton Pump Inhibitors Better than Acid Exposure Time in GERD. Gastroenterology, 2017, 152, S652-S653.	1.3	0
574	Proton Pump Inhibitor Therapy Improves Esophageal Symptoms by Restoring a Normal Esophageal Peristalsis in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. Gastroenterology, 2017, 152, S860.	1.3	0
575	Evaluation of Esophagogastric Junction Contractility after Different Treatments for Achalasia. Gastroenterology, 2017, 152, S1242.	1.3	0
576	OC.15.3: Prevalence and Pathophysiology of Gastro-Esophageal Reflux Disease in Patients with Autoimmune Gastritis. Digestive and Liver Disease, 2017, 49, e121.	0.9	0

#	ARTICLE	IF	CITATIONS
577	Individual Assessment of Gastric Acid Production by Means of a Non-Invasive Test: Relationship between Maximal Acid Output and Pepsinogen I Levels. <i>Gastroenterology</i> , 2017, 152, S471.	1.3	0
578	Update in gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , 2017, 63, 172-174.	0.5	0
579	P.02.12 MICROBIOTA PROFILE AND DYSBIOSIS ASSESSMENT IN CLINICAL PRACTICE: A PILOT STUDY ON IBD PATIENTS. <i>Digestive and Liver Disease</i> , 2018, 50, e137.	0.9	0
580	Letter: oesophageal histological abnormalities and <scp>GERD</scp> â€•an underestimated relationship requiring more attention. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 152-153.	3.7	0
581	P.07.26 QUALITY OF LIFE ASSESSMENT IN ULCERATIVE COLITIS OUTPATIENTS: A CROSS SECTIONAL STUDY. <i>Digestive and Liver Disease</i> , 2018, 50, e204.	0.9	0
582	P.06.26 RISK FACTORS IN GERD: A COMPARATIVE STUDY WITH DYSPEPTIC SUBJECTS ON 2300 PEOPLE IN A PRIMARY CARE SETTING. <i>Digestive and Liver Disease</i> , 2018, 50, e190.	0.9	0
583	P.10.24 VISCERAL ADIPOSE TISSUE QUANTIFICATION ON COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGES: REPRODUCIBILITY AND ACCURACY. <i>Digestive and Liver Disease</i> , 2018, 50, e238.	0.9	0
584	OC.09.3 DYSPHAGIA IS A DRIVEN SYMPTOM ABLE TO PREDICT PERSISTENT EGJ-OUTFLOW OBSTRUCTION DURING A SIX-MONTH FOLLOW-UP: HRM STUDY WITH PROVOCATIVE TEST. <i>Digestive and Liver Disease</i> , 2018, 50, e90.	0.9	0
585	P.07.19 MR-ENTEROGRAPHY WITH AND WITHOUT CONTRAST MEDIA INJECTION: RETROSPECTIVE EVALUATION IN PATIENTS AFFECTED BY CROHN'S DISEASE. <i>Digestive and Liver Disease</i> , 2018, 50, e201.	0.9	0
586	P.06.14 EFFECTIVENESS AND SAFETY OF PYLERA Â® IN PATIENTS INFECTED BY HELICOBACTER PYLORI: A LARGE, PROSPECTIVE, REAL LIFE STUDY. <i>Digestive and Liver Disease</i> , 2018, 50, e184-e185.	0.9	0
587	OC.16.5 IMPACT OF ADALIMUMAB'S PATIENT SUPPORT PROGRAM ON ADHERENCE TO ANTI-TNF-ALFA THERAPY IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER ANALYSIS. <i>Digestive and Liver Disease</i> , 2018, 50, e110.	0.9	0
588	OC.06.5 LOW-FODMAP DIET RESULTED EFFECTIVE IN REDUCING SYMPTOM PERCEPTION IN PATIENTS WITH FUNCTIONAL HEARTBURN: RANDOMIZED, CROSS-OVER CONTROLLED STUDY. <i>Digestive and Liver Disease</i> , 2018, 50, e82-e83.	0.9	0
589	OC.09.5 THE NATURAL HISTORY OF ACHALASIA: EVIDENCE OF A CONTINUUM â€• â€œTHE EVOLUTIVE PATTERN THEORYâ€•. <i>Digestive and Liver Disease</i> , 2018, 50, e91.	0.9	0
590	P.06.9 MULTIPLE RAPID SWALLOW MIGHT BE HELPFUL TO IMPROVE THE DIAGNOSIS OF INEFFECTIVE ESOPHAGEAL MOTILITY. <i>Digestive and Liver Disease</i> , 2018, 50, e182.	0.9	0
591	OC.11.6 POOR CORRELATION BETWEEN ENDOSCOPIC FINDINGS, EOSINOPHILIC INFILTRATION AND REFLUX BURDEN IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. <i>Digestive and Liver Disease</i> , 2019, 51, e108.	0.9	0
592	P.01.2 ESOPHAGO-GASTRIC JUNCTION CONTRACTILE INTEGRAL (EGJ-CI) MAY PREDICT RESPONSE TO TREATMENT IN PATIENTS WITH ESOPHAGEAL ACHALASIA. <i>Digestive and Liver Disease</i> , 2019, 51, e132-e133.	0.9	0
593	â€œLetâ€™s Make Your Clinic Visit a Little Simplerâ€•Development of a Question Prompt List for Adult Patients With Gastroesophageal Reflux Disease: a Modified Delphi Study. <i>Gastroenterology</i> , 2019, 157, e25-e26.	1.3	0
594	P.01.31 A COMPARISON OF DIFFERENT TREATMENTS FOR SYMPTOMATIC REFLUX ESOPHAGITIS: A REAL-LIFE STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e145-e146.	0.9	0

#	ARTICLE	IF	CITATIONS
595	OC.12.4 RAPID POINT-OF-CARE MONITORING OF ANTI-INFLIXIMAB ANTIBODIES AND CLINICAL SCORES IN INFLAMMATORY BOWEL DISEASE PATIENTS. Digestive and Liver Disease, 2019, 51, e110-e111.	0.9	0
596	P.01.12 ON-THERAPY PARAMETERS RATHER THAN OFF-THERAPY IMPEDANCE-PH FEATURES BETTER IDENTIFY PATIENTS WITH NON-EROSIVE REFLUX DISEASE RESPONDING TO PROTON PUMP INHIBITOR THERAPY. Digestive and Liver Disease, 2019, 51, e138.	0.9	0
597	P.02.35 INTESTINAL INVOLVEMENT IN WEGENER'S GRANULOMATOSIS MIMICKING AN INFLAMMATORY BOWEL DISEASE: A CASE REPORT. Digestive and Liver Disease, 2019, 51, e162-e163.	0.9	0
598	P.07.2 DISEASE ACTIVITY INFLUENCES DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – A CROSS-SECTIONAL STUDY. Digestive and Liver Disease, 2019, 51, e221-e222.	0.9	0
599	P.07.17 EFFICACY AND SAFETY OF VEDOLIZUMAB IN REAL LIFE: EXPERIENCE IN A TERTIARY REFERRAL CENTRE. Digestive and Liver Disease, 2019, 51, e229.	0.9	0
600	P.07.28 PREVIOUS EXPOSURE TO INFLIXIMAB INDUCES CROSS-REACTIVITY AND AFFECTS ADALIMUMAB TROUGH LEVELS: DATA FROM A PROSPECTIVE, MULTICENTRE STUDY. Digestive and Liver Disease, 2019, 51, e234.	0.9	0
601	N18 Mood disorders in a IBD population: a single-centre cohort. Journal of Crohn's and Colitis, 2019, 13, S565-S565.	1.3	0
602	OC.09.3 INFLIXIMAB DOSE-REDUCTION IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IN PROLONGED DEEP REMISSION: POTENTIAL IMPLICATIONS ON DE-ESCALATION STRATEGIES IN A REAL LIFE CLINICAL SETTING WITHOUT A THERAPEUTIC DRUG MONITORING (TDM) APPROACH. Digestive and Liver Disease, 2019, 51, e101.	0.9	0
603	P.07.22 HIGH RESOLUTION ANORECTAL MANOMETRY FOR DETERMINATION OF ANORECTAL FUNCTION IN ULCERATIVE COLITIS DURING DISEASE ACTIVITY AND AFTER REMISSION. Digestive and Liver Disease, 2019, 51, e231.	0.9	0
604	OC.10.1 NOVEL MII-PH PARAMETERS ARE ABLE TO DISTINGUISH PATIENTS WITH GERD AMONG SUBJECT WITH EXTRA-ESOPHAGEAL SYMPTOMS. Digestive and Liver Disease, 2019, 51, e103.	0.9	0
605	P.01.25 CAN A NON-INVASIVE TEST PREDICT THE RESULTS OF PH-IMPEDANCE? PROSPECTIVE STUDY OF A COHORT OF PATIENTS WITH EXTRA-ESOPHAGEAL MANIFESTATIONS OF GERD. Digestive and Liver Disease, 2019, 51, e143-e144.	0.9	0
606	OC.12.1 REAL-LIFE EFFECTIVENESS OF USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CONCOMITANT PSORIASIS OR PSORIATIC ARTHRITIS: AN IG-IBD STUDY. Digestive and Liver Disease, 2019, 51, e109.	0.9	0
607	OC.03.3 THE "DICA" ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS. Digestive and Liver Disease, 2019, 51, e84.	0.9	0
608	P.01.9 EFFECTIVENESS OF PEPSINO®, A NOVEL MEDICAL DEVICE CONTAINING HYALURONIC ACID AND ALGINATE, FOR THE TREATMENT OF LARYNGOPHARYNGEAL REFLUX SYMPTOMS. Digestive and Liver Disease, 2019, 51, e136-e137.	0.9	0
609	P.07.32 THE QUALITY OF SLEEP IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS IMPAIRED INDEPENDENTLY FROM THE DISEASE ACTIVITY STATUS – A CROSS-SECTIONAL STUDY. Digestive and Liver Disease, 2019, 51, e236.	0.9	0
610	P.01.8 PROVOCATIVE TESTS DURING HIGH-RESOLUTION MANOMETRY MAY BE HELPFUL TO DISTINGUISH PATIENTS WITH EOSINOPHILIC ESOPHAGITIS RESPONDING TO PPI THERAPY. Digestive and Liver Disease, 2019, 51, e136.	0.9	0
611	P.01.22 A NATIONAL SURVEY ON GASTROENTEROLOGY TRAINING IN ITALY: CURRENT LANDSCAPE AND FUTURE NEEDS. Digestive and Liver Disease, 2019, 51, e142.	0.9	0
612	P.07.33 MICROENCAPSULATED SODIUM BUTYRATE SIGNIFICANTLY MODIFIES THE MICROBIOTA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE MIMICKING PREBIOTIC ACTIVITY AND PROVING EFFECTS ON THE TREATMENT OF THE DISEASE. Digestive and Liver Disease, 2019, 51, e236-e238.	0.9	0

#	ARTICLE	IF	CITATIONS
613	P232 Oesophageal Crohn's disease: diagnosis and outcome of an ECCO-CONFER case series. Journal of Crohn's and Colitis, 2019, 13, S212-S213.	1.3	0
614	P.07.4 HIGH ANTI-TNF ALFA DRUGS TROUGH LEVELS ARE NOT ASSOCIATED WITH THE OCCURRENCE OF ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Digestive and Liver Disease, 2019, 51, e223.	0.9	0
615	P541 Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IBD study. Journal of Crohn's and Colitis, 2019, 13, S384-S385.	1.3	0
616	P465 Therapeutic drug monitoring in Crohn's disease patients, a comparison between homogeneous mobility shift assay and point of care method. Journal of Crohn's and Colitis, 2020, 14, S412-S412.	1.3	0
617	Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations. Digestive and Liver Disease, 2020, 52, 1097-1098.	0.9	0
618	P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study. Journal of Crohn's and Colitis, 2020, 14, S548-S549.	1.3	0
619	T01.02.4 FECAL EOSINOPHIL CATIONIC PROTEIN AS POTENTIAL MARKER OF DISEASE ACTIVITY IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. Digestive and Liver Disease, 2020, 52, S63-S64.	0.9	0
620	T01.02.8 EOSINOPHILIC ESOPHAGITIS - VISUAL SCORE: A NOVEL PICTORIAL SELF-ADMINISTERED TOOL TO ASSESS QUALITY OF LIFE IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. Digestive and Liver Disease, 2020, 52, S65-S66.	0.9	0
621	T01.02.17 CLINICAL USEFULNESS OF SECOND-GENERATION BARRIER DRUGS IN GERD PATIENTS WITH ATYPICAL SYMPTOMS: A-6-MONTHS PROSPECTIVE STUDY. Digestive and Liver Disease, 2020, 52, S69-S70.	0.9	0
622	T01.02.19 IS IT POSSIBLE TO WITHDRAW PPIS THERAPY IN GERD PATIENTS? A PROSPECTIVE STUDY ON 216 PATIENTS USING A SECOND GENERATION BARRIER DRUG. Digestive and Liver Disease, 2020, 52, S70-S71.	0.9	0
623	T01.02.23 ROLE OF ENVIRONMENTAL FACTORS ON THE OUTCOME OF GASTROESOPHAGEAL REFLUX DISEASE: 6 MONTHS PROSPECTIVE STUDY. Digestive and Liver Disease, 2020, 52, S72-S73.	0.9	0
624	T04.02.8 INFlixIMAB ORIGINATOR, INFlixIMAB BIOSIMILAR AND ADALIMUMAB ARE EQUALLY EFFECTIVE AND SAFE IN ULCERATIVE COLITIS AND CROHN'S DISEASE - A REAL-LIFE COHORT STUDY. Digestive and Liver Disease, 2020, 52, S130-S131.	0.9	0
625	Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. Digestive and Liver Disease, 2020, 52, 1252-1253.	0.9	0
626	P843 Intestinal microbiota changes according to disease activity in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S651-S652.	1.3	0
627	99P Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative breast cancer. Annals of Oncology, 2020, 31, S50.	1.2	0
628	P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study. Journal of Crohn's and Colitis, 2020, 14, S397-S397.	1.3	0
629	Reply Letter to "Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes". Neurogastroenterology and Motility, 2021, 33, e14054.	3.0	0
630	Response to Khalaf et al.. American Journal of Gastroenterology, 2021, 116, 1565-1566.	0.4	0

#	ARTICLE	IF	CITATIONS
631	Impact of the Sars-Cov-2 Pandemic on Gastroenterology Units in Italy: a National Survey. , 2021, 53, .		0
632	N11 Complementary and alternative methods to improve quality of life in patients with inflammatory bowel diseases: a systematic literature review. Journal of Crohn's and Colitis, 2021, 15, S613-S614.	1.3	0
633	P329 Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, S353-S353.	1.3	0
634	P506 The Impact of Anxiety in Patients With Inflammatory Bowel Diseases Treated With Biologics during COVID Lockdown. A Comparative Study between Hospitalized and non-hospitalized patients. Journal of Crohn's and Colitis, 2021, 15, S487-S488.	1.3	0
635	P295 Comparative Assessment of Infliximab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, S325-S325.	1.3	0
636	P216 Comparative Assessment C-reactive Protein Between a Point-of-Care Testing and Current Standard of Care (Immunonephelometric testing). Journal of Crohn's and Colitis, 2021, 15, S272-S273.	1.3	0
637	Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1077-1078.	4.4	0
638	P124 Gastroenteropancreatic Neuroendocrine Neoplasms in patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. Journal of Crohn's and Colitis, 2021, 15, S215-S216.	1.3	0
639	Editorial: postâ€reflux swallowâ€induced peristaltic wave in eosinophilic oesophagitisâ€”more questions than answers? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 190-191.	3.7	0
640	ID: 3522469 RISK OF COVID-19 TRANSMISSION AND OUTCOMES IN HEALTHCARE WORKERS PRESENT DURING GASTROINTESTINAL ENDOSCOPIC PROCEDURES: AN INTERNATIONAL MULTICENTER STUDY. Gastrointestinal Endoscopy, 2021, 93, AB45-AB46.	1.0	0
641	OC.01.10 EGJ OUTFLOW OBSTRUCTION ACCORDING TO THE NEW CHICAGO CLASSIFICATION: HOW MANY DIAGNOSES MIGHT BE CONFIRMED?. Digestive and Liver Disease, 2021, 53, S97.	0.9	0
642	AF.15 EOSINOPHILIC ESOPHAGITIS IS FREQUENTLY ASSOCIATED WITH DISORDERS OF PERISTALSIS AT HIGH-RESOLUTION MANOMETRY: A PROSPECTIVE SINGLE-CENTRE CASE-CONTROL STUDY. Digestive and Liver Disease, 2021, 53, S143-S144.	0.9	0
643	AF.48 COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Digestive and Liver Disease, 2021, 53, S158.	0.9	0
644	OC.01.5 RAPID DRINK CHALLENGE DURING HIGH RESOLUTION MANOMETRY IS USEFUL TO PREDICT ESOPHAGEAL EMPTYING IN ACHALASIA PATIENTS AFTER TREATMENT. Digestive and Liver Disease, 2021, 53, S94-S95.	0.9	0
645	Esophageal Motility Testing: The Present and the Future. , 2017, , 201-215.		0
646	The Diagnostic Yield of Novel Parameters in Reflux Monitoring. , 2017, , 217-227.		0
647	A Non-Invasive Serological Test to Assess the Efficacy of Biologic and Non-Biologic Therapies on the Mucosal Health of Patients With Crohn's Disease. American Journal of Gastroenterology, 2017, 112, S401-S402.	0.4	0
648	Authorsâ€™ reply. Annals of Gastroenterology, 2019, 32, 319.	0.6	0

#	ARTICLE	IF	CITATIONS
649	Prevalence of Anxiety and Depression in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0
650	P044 Enteric dopaminergic pathways in mouse and human intestinal inflammation. Journal of Crohn's and Colitis, 2022, 16, i160-i161.	1.3	0
651	P119 Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series. Journal of Crohn's and Colitis, 2022, 16, i210-i210.	1.3	0
652	P014 Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmission. Journal of Crohn's and Colitis, 2022, 16, i142-i142.	1.3	0
653	Pharmacotherapies in eosinophilic esophagitis: state of the art. Minerva Gastroenterology, 2022, 68, 69-76.	0.5	0
654	Eosinophilic esophagitis: a rising disease. Minerva Gastroenterology, 2022, 68, .	0.5	0
655	Editorial: Lyon consensus metricsâ€”towards personalised diagnosis of nonâ€erosive reflux disease: Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1216-1217.	3.7	0
656	OC.05.4 SYSTEMATIC REVIEW WITH META-ANALYSIS: ARTIFICIAL INTELLIGENCE IN THE DIAGNOSIS OF ESOPHAGEAL DISEASES. Digestive and Liver Disease, 2022, 54, S80-S81.	0.9	0
657	T.01.1 APPLICATION OF LYON CONSENSUS CRITERIA FOR GERD DIAGNOSIS: EVALUATION OF PATIENTS WITH INCONCLUSIVE DIAGNOSIS AND NEW IMPEDANCE-PH PARAMETERS. Digestive and Liver Disease, 2022, 54, S115.	0.9	0